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I. INTRODUCTION

With the 2020 presidential election looming, healthcare
reform is emerging as a major campaign issue. Numerous ideas,
from creation of a national single payer system, to major
overhauls of Medicare/Medicaid, to significantly revising
coverage requirements mandated under the Affordable Care Act,
are in play. While the scope and details of health reform
proposals are highly variable, the underlying issues, which any
significant reform initiative will face, are universal and constant.
Undoubtedly, the biggest challenge all health reform proposals
confront concerns crafting innovative and meaningful approaches
to addressing the pervasive fiscal pressures faced by government
programs. There is a long history of attempts to "bend the cost
curve," but this complex task remains elusive in the face of
evolving demand and supply side pressures.1 One large point of
consensus in the complex arena of cost containment policy is a
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1 See Ehsan U. Syed, Will We Ever Bend the Cost Curve in Healthcare?,AM.

HEALTH

& DRUG BENEFITS (July 2019), http://www.ahdbonline.com/issues/2019/june-july-2019-vol12-no-4/2789-will-we-ever-bend-the-cost-curve-in-healthcare [http://perma.cc/ABN5-LY8Z].
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general agreement that there must be a direct assault on chronic
health diseases, such as obesity, heart disease, and cancer. It is
estimated by the Centers for Disease Control and Prevention
("CDC") that six in ten adults suffer from at least one chronic
disease, and that this category of illnesses is a major driver of our
nation's $3.3 trillion in healthcare costs. 2 No comprehensive
health reform can succeed unless it promotes strategies to
effectively mitigate the burden of chronic diseases.
Few chronic diseases have a greater impact on health costs
than substance use disorders. While opioid addiction may be the
most current and visible form of substance use disorders, it is
part of a broader, ongoing epidemic that includes the abuse of
licit and illicit drugs, as well as alcohol. 3 One of our nation's
oldest substance use disorders is cigarette smoking-a behavior
that is driven by nicotine, the highly addictive chemical found in
tobacco. 4 Cigarette consumption is widely recognized as leading
to multiple, serious health problems. 5 It is an ongoing public
health epidemic and has been the focus of regulators and health
organizations since the release of the U.S. Surgeon General's
Report on Smoking in 1964.1 In the many years in which a war
against tobacco has been waged by public and private actors,
great progress has been made in reducing the number of smokers
in the U.S. from 43% in 1965 to less than 16% currently.7 But
even in the face of progress, cigarette smoking remains our most
preventable cause of death-higher than AIDS, alcoholism,

2 Chronic Diseases in America, NATL CTR. FOR CHRONIC DISEASE PREVENTION & HEALTH
PROMOTION, http://www.cdc.gov/chronicdisease/pdf/infographics/chronic-disease-H.pdf

[http://perma.cc/SKU5-WKLF] (last updated Sept. 12, 2019). It has also been estimated
that four in ten adults suffer from two or more chronic health conditions. Id.
3 See Trends & Statistics, NAT'L INST. ON DRUG ABUSE, http://www.drugabuse.gov/
related-topics/trends-statistics [http:perma.cc/2Y3F-TZJQ] (last updated Apr. 2017)
(estimating the health costs of substance use disorders to be as high as $250 billion
annually). For further details on the opioid epidemic, see What is the U.S. Opioid
Epidemic?, U.S. DEP'T OF HEALTH & HUMAN SERVS., http://www.hhs.gov/opioids/about-

the-epidemic/index.html [http://perma.cc/4MGT-YLUL] (last updated Sept. 4, 2019).
4 See Is nicotine addictive?, NAT'L INST. ON DRUG ABUSE, http://www.drugabuse.gov/
publications/research-reports/tobacco-nicotine-e-cigarettes/nicotine-addictive
[http://perma.cc/5VQU-B74A] (last updated Oct. 2019) (discussing the addictive
properties of nicotine).
5 See Kayla Ruble, Read the Surgeon General's 1964 Report on Smoking and Health,
PBS (Jan. 12, 2014, 2:00 PM), http://www.pbs.org/newshour/health/first-surgeon-generalreport-on-smokings-health-effects-marks-50-year-anniversary [http://perma.cc/8P85-ELVR].
6 See id.
7 See Smoking is down, but almost 38 Million American adults still smoke, CTRS.
FOR DISEASE CONTROL & PREVENTION (Jan. 18, 2018), http://www.cdc.gov/media/releases/
2018/pOl18-smoking-rates-declining.html [http://perma.cc/YEG8-YE8E]; Smoking in
America: Why more Americans are kicking the habit, AM. HEART ASS'N (Aug. 30, 2018),
http://www.heart.org/en/news/2018/08/29/smoking-in-america-why-more-americans-arekicking-the-habit [http://perma.cc/EYR8-EB9E].
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murder, suicide, and use of illegal drugs combined.8 According to
the CDC, smoking-related illnesses cost more than $300 billion a
year in direct medical expenses and lost productivity; it is an
addiction that accounts for 8.7% of healthcare spending, of which
60% is paid for by public sources. 9 The burdens of smoking on our
health delivery system continue to be profound and any success
we may have in containing healthcare costs will be realized only
by continuation of the decades-long struggle to mitigate the
tobacco epidemic.
The so-called war against tobacco has a long, detailed, and
well-documented history that spans the second half of the
twentieth century and continues to the present.10 This robust
history of regulation reveals an assortment of abatement
strategies that pit public health actors against individual
smokers, powerful manufacturers, retailers, and agricultural
interests. Central to this history is the role of law as a basic tool
to implement an array of public policies and interventions on
both domestic and international levels.1 1 The ubiquitous presence
of law in the struggle against tobacco products has been divided
into two distinct periods: the first being a long period in which
the focus of regulation rests on tobacco as an agricultural
product, and the second characterized by public protection, in
which preventing and reducing the health impacts of
consumption is dominant. 12 These two periods-private market
regulation and public health oversight-are not sequential, but
13
coexist as major focal points of activity.
For decades, the regulation of tobacco as a private product has
focused on farming policies, product taxation, and various
14
attempts to promote market competition through antitrust law.

8 See U.S. DEP'T HEALTH & HUMAN SERVS., THE HEALTH CONSEQUENCES OF
SMOKING-50 YEARS OF PROGRESS: A REPORT OF THE SURGEON GENERAL 678-79 (2014);
Smoking and Death, CTRS. FOR DISEASE CONTROL & PREVENTION (Jan. 17, 2018),

http://www.cde.gov/tobacco/data-statistics/fact-sheets/health-effects/effects-cig-smoking/
index.htm [http://perma.cc/D7HP-UNVD].
9 Fast facts, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/

data statistics/fact sheets/fast facts/index.htm [http://perma.cc/N5Q8-GZDF] (last updated
Feb. 6, 2019); Xin Xu et al., Annual Healthcare Spending Attributable to Cigarette Smoking,
48 AM. J. PREVENTATIVE MED. 326, 331 (2015).

io See Helene M. Cole & Michael C. Fiore, The War Against Tobacco: 50 Years and
Counting, 311 JAMA 131-32 (2014) (providing a summary of the turn of public health
policy against tobacco).
ii For an overview of the long history of tobacco regulation, see NAT'L COMM N ON
MARIHUANA & DRUG ABUSE, History of Tobacco Regulation, 1 APPENDIX: MARIHUANA: A
SIGNAL OF MISUNDERSTANDING
514 (1972), http://hdl.handle.net/2027/umn.31951d
03118410v [http://perma.cc/J8ND-T8KP].
12 See id.
13 See GIDEON DORON, THE SMOKING PARADOX 5 (Michael Connolly et al. eds., 1979).

14 See id. at 5-12.
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The focus on public health regulation can be traced to a growing
awareness of the correlations between smoking and disease that
15
has gone from anecdotal speculation to scientific certainty.
Public good regulations are characterized by a host of mandates,
from labeling and advertisement requirements, to age restrictions,
to product content oversight. 16 The legal system's impact on
smoking has arisen from a m6lange of statutory directives at all
levels of government, in addition to litigation-particularly the
1998 Master Settlement Agreement that promoted widespread
17
adoption of restrictions on tobacco products.
A central feature in any consideration of tobacco control
concerns the response of the regulated. The growing,
manufacturing, and selling of tobacco products is a large,
sophisticated, and profitable industry, and even in the face of
long-term scrutiny, this sector has been able to adjust to
regulations by adopting strategies of aggression
and
accommodation as needed. Paradoxically, the tobacco companies
that adamantly denied that smoking caused health problems
during the twentieth century, now caution against this behavior,
positing smoking as a matter of adult choice and advocating that
18
smokers switch to their newest product line, e-cigarettes.
This Article offers commentary on one legal strategy that has
been used in the long-term struggle to control tobacco: the use of
package warning labels. First introduced in 1965 in the Federal
Cigarette Labeling and Advertising Act ("FCLAA," also referred
to as the Cigarette Act), a label-warning mandate has since
become a basic feature of tobacco regulation.1 9 It is the second
piece of federal legislation enacted during the 91st Congress, the
Public Health Cigarette Smoking Act ("PHCSA"), 20 that modified
cigarette label warning requirements and which will be the
springboard for analysis in this Article. This piece will explore
the evolution and changes in the law concerning federal cigarette
package warnings, tracing legislative iterations in the area from
a basic textual requirement originating in the 1960s, 21 to the
15 See id. at 12-15.
16 See id. at 14-19.
17 See Pete Levin, The ABCs of the Tobacco Master Settlement Agreement,
2 NAAG, Nov. 6, 2007, at 1-2, http://www.naag.org/assets/files/pdf/gazette/1.2.Gazette.pdf
[http://perma.cc/U49K-7PEL].
18 See E-Cigarettes: Facts, stats and regulations, TRUTH INITIATIVE (July 19, 2018),

http://truthinitiative.org/research-resources/emerging-tobacco-products/e-cigarettes-factsstats-and-regulations [http:perma.cc/TR9S-SSEC].
19 Federal Cigarette Labeling and Advertising Act, Pub. L. No. 89-92, 79 Stat. 282
(codified in 15 U.S.C. §§ 1331-1336, 1338-1340 (2012)).
20 Public Health Cigarette Smoking Act of 1969, Pub. L. No. 91-222, 84 Stat. 87
(codified in 15 U.S.C. § 1340 (2012)).
21 See id.
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much more complex requirement to add graphic health warnings
enacted in 2009.22 Undoubtedly the issue of tobacco warning
labels is only one of many threads in the larger context of
cigarette regulation, but it is one which provides a helpful
window into the exploration of policies to address the public
health epidemic of smoking. The adoption and changes to
warning labels reflect the historic environments in which such
anti-smoking policies were developed and demonstrate an
ongoing tension between regulators and industry. While tobacco
control is a pillar of public health, it is not an exact science, as
best practices, such as warnings, are difficult to measure and
uncertain in the face of evolving smoking practices, like the use of
e-cigarettes. As in other areas of smoking policy, political and legal
impediments abound in the warning arena, compromising
government capabilities to find an endgame to this persistent
epidemic. The goal of this Article is to identify lessons that can be
garnered from a review of the law concerning cigarette-package
warnings to both improve that process and, more broadly, confront
the ongoing challenges smoking poses to our healthcare system.

II. BACKGROUND
The rise and fall of cigarettes is a story ingrained in the
twentieth century. The combination of mass production and
skillful marketing moved the cigarette from relative obscurity in
1900 to a central place in American life by the 1930s.2 3 While
tobacco use exploded both domestically and internationally, it
was cigarette consumption that dominated and became the
epicenter of this behavior.2 4 Cigarettes were marketed as highly
desirable products, and ads depicting smoking as tasteful,
healthy, and refreshing were seen for years in all forms of
advertising media.2 5 The advertisements were diverse in
character, with various brands arguing that their products were

22 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123
Stat. 1776 (codified in 21 U.S.C. §§ 387, 387a-387u, 387a-1, 387f-1 (2012)).
23 See ALLAN M. BRANDT, THE CIGARETTE CENTURY: THE RISE, FALL AND DEADLY
PERSISTENCE OF THE PRODUCT THAT DEFINED AMERICA 2-3 (2007).

24 See id. at 97.
25 See Cigarette Advertising Themes, STAN. UNIV., http://tobacco.stanford.edu/
tobacco main/main.php [http://perma.cc/E8QZ-N36L] (last visited Sept. 18, 2019).
Cigarette advertisements are iconic symbols of American life, often depicting well-known
personalities of the day touting the attractiveness of smoking as healthful and refreshing.
See id. A prime example of characteristic advertising can be found on the pages of
America's most popular weekly magazine, Life Magazine; the back-cover page of the
magazine was often devoted to full page, artful tobacco advertisements that are reflective
of the culture surrounding cigarettes. See Stuart Elliot, Once a Mainstay of Magazines,
Cigarette Makers Drop Print Ads, N.Y. TIMES (Nov. 29, 2007), http://www.nytimes.com/
2007/11/29/business/media/29adco.html [http://perma.cc/8YR8-UGTG].
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less irritating to the smoker's throat, thereby 26cloaking
themselves in the imprimatur of medical endorsements.
At the time cigarette smoking was reaching its zenith, seeds
of concern about the health implications had been widely sown.
In the early part of the twentieth century, criticism of cigarettes
on moral grounds was as common as concerns over health, which
somewhat paralleled reactions against alcohol use. 27 The public
health case against cigarettes evolved over a considerable period
of time as the epidemiological proof linking smoking with cancer
became more convincing and spilled over from scientific
literature into every day parlance. 28 Tobacco companies
vigorously fought back, orchestrating a massive public relations
effort to empathize with health concerns, while simultaneously
calling into question the29 validity of the science linking cigarette
consumption to disease.
In the 1940s and 1950s, the tobacco industry challenged the
validity of anti-smoking studies, and even financed its own
research that called into question claims that the product was a
gateway to serious health problems. 30 In addition to adopting a
posture of aggressive denials over health claims, tobacco
manufacturers began to introduce filtered cigarettes to reduce
harmful tar and nicotine content, which paradoxically should not
have been necessary had these products not been potentially
harmful to begin with. 31 Another popular strategy used to market
cigarettes was for manufacturers to make claims about the low
levels of tar and nicotine in a given brand, arguing the result was
less throat irritation, and, by implication, constituted a healthier
product. 32 As more scientific research about the ills of smoking
unfolded, the industry shifted from a rejection of causation to
arguments that there was simply inadequate proof about the
dangers of smoking to reach a definitive conclusion. 33 Through
much of the twentieth century, cigarettes were largely

26 See Martha M. Gardner & Allan M. Brandt, "The Doctors' Choice Is America's
Choice": The Physician in U.S. Cigarette Advertisements, 1930 1953, 96 AM. J. PUBLIC
HEALTH 222, 223-24 (2006).
27 Id. at 222; see U.S. DEP'T HEALTH & HUMAN SERVS., THE HEALTH CONSEQUENCES
OF SMOKING-50 YEARS OF PROGRESS: A REPORT OF THE SURGEON GENERAL 19 (2014).

28 See Gardner & Brandt, supra note 26, at 222-23.
29 See id. at 223.
30 See Allan M. Brandt, Inventing Conflicts of Interest: A History of Tobacco Industry
Tactics, 102 AM. J. PUBLIC HEALTH 63, 63-64 (2012).
31 See Gardner & Brandt, supra note 26, at 229-30.
32 Joel B. Cohen, Smokers' Knowledge and Understanding of Advertised Tar
Numbers: Health Policy Implications, 86 AM. J. PUBLIC HEALTH 18, 19 (1996).
33 See STANTON A. GLANTZ ET AL., THE CIGARETTE PAPERS 25 (1996) ("After millions
of dollars and over twenty years of research, the question about smoking and health is
still open.").
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unregulated, with the exception of Federal Trade Commission
("FTC") oversight, which had control over unfair trade
practices. 34 The FTC did issue a number of cease and desist
orders involving various advertising claims made in particular
cigarette brand ad campaigns, but it lacked the capacity to
contain an industry that was able to nimbly adjust advertising
strategies to circumvent regulatory challenges. 35 Following
Congressional tobacco hearings in 1957 that highlighted the
deceptive nature of tobacco advertising, a movement to attach
36
warning labels to cigarette packaging developed.
Eventually the weight of science pressured the government
to take action to evaluate the accumulating evidence linking
smoking and illness, and a government commission was created
in 1962 under the auspices of the U.S. Surgeon General to look
into the matter. 37 In early January of 1964, the U.S. Surgeon
General's Advisory Committee on Smoking and Health issued
what has become a seminal report in the history of tobacco
control. 38 It was a catalyst in the design of multidisciplinary
health studies, which also sparked subsequent Surgeon General
39
smoking evaluations.
The Surgeon General's Report, based on review of over 7,000
articles on smoking and health, concluded "that cigarette
smoking is-[a] cause of lung and laryngeal cancers in men[,] a
probable cause of lung cancer in women[J" as well as a "cause of

34 See Federal Trade Commission Act, 15 U.S.C. § 49 (Supp. IV 1970) (using the
subpoena power to investigate instances of unfair methods of competition).
35 See Statement of Basis and Purpose for the Cigarette Advertising and Labeling
Trade Regulation Rule, 29 Fed. Reg. 8325 (July 2, 1964). On September 15, 1955, the FTC
issued cigarette-advertising guides. 1960 FTC ANN. REP. at 82. Among other things, they
prohibit representations in cigarette advertising or labeling which refer to the presence or
absence of any physical effects from cigarette smoking or which make any
unsubstantiated claims respecting nicotine, tar or any other components of cigarette
smoke, or in any other respects contain misleading implications concerning the health
consequences or the advertised brand. See id. at 83. In 1960, the Commission obtained the
agreement of the leading cigarette manufacturers to discontinue the misleading and
unsubstantiated representations of tar and nicotine content which had characterized the
so-called tar derby. See id. The FTC was limited in its regulatory authority over tobacco
as the additional authority granted to the FTC in 1938 through the Food, Drug, and
Cosmetic Act did not include tobacco; it took time for the Commission to ban tar and
nicotine content, as unsubstantiated health claims, lacking in proof or uniform testing.
Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (Supp. IV 1930) (codified as
amended in scattered sections of 21 U.S.C.).
36 See BRANDT, supra note 23, at 246.
37 See id. at 219.
38 U.S. DEP'T HEALTH, EDUC., & WELFARE, PUB. HEALTH SERV. PUB. No. 1103,
SMOKING AND HEALTH: REPORT OF THE ADVISORY COMMITTEE TO THE SURGEON GENERAL
OF THE PUBLIC HEALTH SERVICE (1964).
39 Id.
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chronic bronchitis." 40 The report did not end scientific issues
concerning cigarette smoking, but did resolve any uncertainty
about whether there was a link between tobacco and illness, and
as such, created an avenue for government to more forcefully
address the smoking problem directly.
The Surgeon General's Report emerged in a period where
smoking rates were high and, as noted, product regulation over
cigarette content and manufacturing processes was largely
non-existent. With cigarettes established as a type of disease
vector by the Surgeon General, the initial focus of federal
regulatory activity was centered on addressing the myths
spawned by aggressive and misleading ad claims. 41 The challenge
of moving the report from a scientific analysis to remedial action
fell to the FTC, which quickly unveiled a new set of regulations
that mandated warnings about the dangers of smoking under the
Commission's authority to safeguard against unfair and
deceptive trade practices. 42 The FTC issued a proposed rule,
which, in part, specified that one of two prescribed warnings be
prominently displayed in all advertisements and on every
43
cigarette pack, box, or container, as well as in advertisements.
This FTC rulemaking sparked a national debate on cigarette
regulation that shifted the issue from a question of science to one
of politics, and raised questions about the scope of regulatory
authority in this arena. While the FTC proposal to add powerful
warnings concerning the dangers of smoking garnered strong
support from most public health groups, surprisingly the
American Medical Association ("AMA") did not endorse tobacco
warning labels, but instead, for political reasons, called for
increasing research into the public health implications of
smoking, rather than adoption
of warnings that the AMA felt
44
would likely be ignored.

40 History of the Surgeon General's Reports on Smoking and Health, CTR. FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/data-statistics/sgr/history/

index.htm [http://perma.cc/2M8P-49UD] (last updated Dec. 18, 2018). The Report
concluded that the death rates for male smokers from lung cancer were 1,000% higher
than male nonsmokers. BRANDT, supra note 23, at 224.

41 See Advertising and Labeling of Cigarettes, 29 Fed. Reg. 530, 530-32 (Jan. 22, 1964).
42 See id.
43 M. JOYCELYN ELDERS, PREVENTING TOBACCO USE AMONG YOUNG PEOPLE: A

REPORT OF THE SURGEON GENERAL 257 (1994) (stating, caution: (a) "The Surgeon
General's Advisory Committee on Smoking and Health has found that cigarette smoking
contributes substantially to mortality from certain specific diseases and to the overall
death rate"; or (b) "Cigarette smoking is dangerous to health. It may cause death from
cancer and other diseases.").
44 It has been suggested that the AMA was caught up in its fights against Medicare
and Medicaid legislation and did not want to alienate tobacco state members of Congress.
BRANDT, supra note 23, at 249. In a JAMA editorial, the Executive Director of the AMA
argued that tobacco had such large and multi-faceted implications that Congress, and not
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While the science linking smoking to disease was advanced
by the Surgeon General's Report, the tobacco war quickly took on
a strong public policy cast as the tobacco lobby, shifted its efforts
to the political arena, and waged its battles in Congress. Tobacco
had powerful allies in Congress, led by members from tobacco
growing states who had close ties to President Lyndon
B. Johnson. 45 While the FTC was pushing for greater regulatory
control over cigarettes, the tobacco industry went on the offensive
by threatening litigation to block the Commission's expansion of
tobacco regulations and proposing its own legislative fixes, which
were reflected in Senate Bill 559. 46 Striking testimony in
Congressional tobacco hearings was provided by some of the
nation's leading cancer specialists who argued that the statistical
link between smoking and health was not powerful enough to
47
discount other multiple causes that might underlie lung cancer.
At this point, the tobacco lobby recognized that the
pendulum of science and public opinion about smoking had
shifted, thereby making warnings inevitable. So, rather than
fight this development, it supported a very diluted
warning: "Caution: Cigarette Smoking May Be Hazardous to
Your Health."48 Ironically, while the smoking lobby continued to
question the science around this behavior as uncertain, it
supported a warning label as a mechanism to notify consumers
about the dangers of smoking, and as a strategy to mitigate
potential liability, thus creating an assumption of risk on the
part of the smoker. 49 In addition, the industry sought to restrict
FTC regulation and supported placing future labeling and
advertising regulations in Congressional control, preempting
state and local activities in this area. 50 On another front, a
Tobacco Industry Code of Advertising was adopted in 1964.51 The
Code was a form of self-regulation, directed at prohibiting ads
geared toward youth smoking, ensuring accuracy in health

a regulatory agency, should control labeling and advertising. F.J.L. Blasingame, Full Text
of AMA Letter of Testimony to FTC, in 188 JAMA 31, 31 (1964). In addition, the Tobacco
Research Industry Committee in 1964 (renamed the Council for Tobacco Research) had
pledged $10 million to the AMA Education and Research Foundation to conduct research
into the possible association between smoking and health. See 21 CONG. Q. SERV., Health
Warning Required on Cigarette Packs, in XXI CONG. Q. ALMANAC 344 (Henrietta Poynter
et al. eds., 1965).
45 See CONG. Q. SERV., supra note 44, at 344.

46 See id. at 344-45.
47 See id. at 348.
48 See id. at 345.
49 See BRANDT, supra note 23, at 254.
50 Id.

51 John W. Richards, Jr. et al., The Tobacco Industry's Code of Advertising in the
United States: Myth and Reality, 5 TOBACCO CONTROL 295, 295 (1996).
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claims, and creating an administrative mechanism
to vet
52
advertisements based on the first two objectives noted.
In July of 1965, the FLCAA was signed into law by President
Lyndon B. Johnson, despite the White House failing to endorse
this bill and a lack of unanimity in the Executive branch about
how tobacco control should be developed. 53 Opposition from key
members of Congress, who feared any federal legislation that
might adversely impact the economics of tobacco growing and
product taxation, certainly played a critical role in what was
contained in this legislation. 54 The tobacco lobby heavily
influenced this federal law, and the conditions noted above
(warning labels, preemptions, regulatory agency limitations)
were incorporated into this statute, making it a very pro-industry
enactment. 55 Nonetheless, even if the law was highly
compromised, The Cigarette Act remains significant, as it was
the first of several pieces of federal legislation enacted to regulate
tobacco products, and represents a foundation on which
subsequent tobacco legislation rests. The Cigarette Act required
a conspicuous package-warning label that codified the explicit
language to be included, by January 1966, on all domestic and
imported cigarette packaging. 56 The warning mandate was a step
towards the legal recognition of the dangers of smoking that had
been endorsed by the U.S. Surgeon General as a matter of public
education, even if it was much less stringent than what health
advocates had hoped for. 57 The Cigarette Act placed a four-year
moratorium on any additional federal, state, or local agency
regulation of advertisements, as well as restricted federal
agencies from requiring language in warning labels beyond what
was specified in the statute. 58 While the FTC still retained its
general powers to regulate cigarettes under its authority over
unfair and deceptive trade practices, the FCLAA moratorium
shifted power to Congress and struck a blow against agency
autonomy in this field. 59 The law required that the Department
of Health, Education, and Welfare ("DHEW") submit regular
reports to Congress about the health consequences of smoking,
52 Id.

53
54
55
56

Federal Cigarette Labeling and Advertising Act, 15 U.S.C. §§ 1331-1341 (1966).
See CONG. Q. SERV., supra note 44, at 346.
See id. at 345-46.
Id. at 345.

57 See NAT'L COMMN ON MARIHUANA & DRUG ABUSE, supra note 11, at 523.

58 Id. The law prohibited the FTC from requiring that the warning be placed in tobacco
advertisements. For a discussion of the preemption question that was later dealt with by the
U.S. Court, see CONG. RESEARCH SERV., R40639, THE FEDERAL CIGARETTE LABELING AND
ADVERTISING ACT AND PREEMPTION REVISITED: AN ANALYSIS OF THE SUPREME COURT CASE
ALTRIA GROUP, INC. V. GOOD AND CURRENT LEGISLATION 14-16 (2009).
59 See NAT'L COMMN ON MARIHUANA & DRUG ABUSE, supra note 11, at 523.
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and that the FTC submit reports on the effectiveness of labeling
and the impacts of advertising on smoking.6 0
III. THE PUBLIC HEALTH CIGARETTE SMOKING ACT AND THE
91ST CONGRESS

Through ongoing research in the 1960s, it became clearer
that smoking causes multiple health problems and that this
awareness was taking root in the public consciousness.6 1 On the
other hand, tobacco sales were at their zenith and smoking rates
even increased in 1966 after mandated package-warning labels
were legislated in the FCLAA.6 2 The economic power of the
tobacco industry and the success of cigarette advertising made
smoking a difficult target for public health advocates.6 3 But there
were broader societal health concerns beyond smoking-such as
increasing cancer rates generally and growing fears over
illnesses caused by environmental toxins-that affected the
regulatory climate of the 1960s.6 4 In addition, it was during this
time that the country experienced the growth of the consumer
movement, in which an emphasis on safety, information, choice,
and redress emerged as legal levers to empower individuals in
the face of large corporate interests.6 5 These broad societal forces
came together during the Nixon administration and it was in this
period that the 91st Congress was confronted with deciding what
should be included in a new tobacco law in light of the sunset of
key portions of FCLAA-particularly those concerning agency
authority and package warning requirements.
The concerns about the ill effects of cigarettes did not
subside after the passage of the FCLAA, but continued into the
late 1960s, driven to a considerable extent on the political side by
the Nixon administration's U.S. Surgeon General, Jesse
Steinfeld. 6 Dr. Steinfeld, a cancer researcher from the National
Cancer Institute, was a very strong anti-smoking advocate who
used his position as Surgeon General as a bully pulpit to attack
the tobacco industry; he argued that tobacco companies were

See id.
See id.
See id.
See id.
See Robert Lichter, Stop the FearmongeringOver Cancer, FORBES (June 1, 2010, 11:24
AM), http://www.forbes.com/20 10/06/0 1/cancer-hystena-health-media-opinions-columnists-roberthchter.html# 163564cc3348 [http://perma.cc/M99L-24UH].
65 See Richard L. Worsnop, Directions of the Consumer Movement, in CQ
60
61
62
63
64

RESEARCHER 3-4 (1972).
66 See Alison Snyder, Jesse Steinfeld, 384 LANCET 1258, 1258 (Oct. 4, 2014),

http://www.thelancet.com/journals/lancet/article/PIIS0 140-6736(14)6 1760-8/fulltext
[http://perma.cc/6FD7-BUHA].
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responsible for millions of related deaths.6 7 Particularly
noteworthy was Steinfeld's campaign that cautioned women
about the dangers of smoking while pregnant or near children,
and his pioneering work in raising concern about the dangers of
secondhand smoke that underpinned a call to ban smoking in
public places.68 Steinfeld's vigorous advocacy proved controversial
and unpopular with key political operatives in the Nixon
administration who feared backlash from the tobacco industry
and political fallout in states that were heavily dependent on this
crop as a mainstay of their agricultural economies.6 9 It was also
argued that the Surgeon General was overly concerned with the
health impacts of smoking, at the expense of taking action to
70
combat other health hazards.
In the period following the FCLAA, a number of important
smoking-related developments occurred beyond the vigorous
anti-smoking advocacy of the Surgeon General. In 1966, a
request was made to television station WCBS to broadcast
anti-smoking announcements under the equal time provisions of
the fairness doctrine.7 1 During this era, cigarettes were the
leading product advertised on television, accounting for 8% of
advertising time. 72 The argument was made that the law
governing broadcast media required that airtime also be allotted
to public health advocates to present information about the
health risks of smoking to counter the false representations made
in cigarette commercials.7 3 The Federal Communications
Commission ("FCC") supported the use of the fairness doctrine to
counteract cigarette ads as a matter of public interest. 74 Later
use of this doctrine was upheld in the federal courts where the
argument that it violated First Amendment commercial speech
protections was rejected.7 5 While "equal time" was not required
for anti-tobacco ads, broadcasters were required to devote a
"significant amount of time" to free messages that educated the

67

Id.

68 Id.
69 "Any attacks on tobacco are counter-productive in Kentucky, North Carolina and
Virginia, where tobacco-growing and manufacturing are vital to the economy. The same is
true to a lesser, but still significant, extent in Tennessee, Georgia, South Carolina, Florida
and Maryland." Memorandum for the Att'y Gen. from Lee R. Nunn, Comm. for the
Re-Election of the President (Jan. 18, 1972).
70 See id. at Attachment C.
71 NATL COMMN ON MARIHUANA & DRUG ABUSE, supra note 11, at 524.
72 SUSAN WAGNER, CIGARETTE COUNTRY: TOBACCO IN AMERICAN HISTORY & POLITICS

166 (1971).
73 See Banzhafv. FCC, 405 F.2d 1082, 1086 (D.C. Cir. 1968).
74 See id. at 1087.
75 See id. at 1100-01.
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public about the hazards of smoking, and as such, frequent
anti-tobacco spot ads began to populate the broadcast airwaves. 76
Under the dictates of the FCLAA, the FTC was temporarily
prevented from implementing any requirement that tar and
nicotine content be listed on cigarette packages. 77 Still, the FTC,
after many years of rejecting industry claims concerning
cigarette content, reached a private agreement with tobacco
manufacturers in 1966 to allow tar and nicotine content to be
advertised. 78 The Commission had convened a panel of scientists
to explore the tar and nicotine issue. 79 This panel concluded that
there was sufficient evidence to support the claim that cigarette
smoke that contained lower amounts of these two substances was
less harmful and that recommendations should be made to the
Surgeon General to support reduction of these harmful chemicals
in cigarette smoke. 80 Cigarette manufacturers were not required
to include tar and nicotine content in advertisements, but could
choose to do so without facing a regulatory penalty. 8 1 The FTC
required that advertised ingredients be based on accepted smoke
testing procedures, even endorsing a particular testing method,
82
and creating its own laboratory to conduct smoke tests.
In 1967, the FTC released a report on cigarette labeling and
advertising, required under FCLAA. 83 This report, based on
survey data collected from public health professionals and
consumers, concluded there was no evidence that the current
label warning required in 1965 had any effect on cigarette
consumption. 84 In fact, in the first two months after the warning
appeared, product sales actually increased. 85 Survey respondents
overwhelmingly reported that they felt that the current warning
label language was insufficient to inform the public of the
general hazards of smoking, particularly in the face of massive

76 Id. at 1086-87.
77 NAT'L COMMN ON MARIHUANA & DRUG ABUSE, supra note 11, at 523.
78 See Vanessa K. Burrows, CONG. RESEARCH SERV., RS22944, FEDERAL TRADE
COMMISSION GUIDANCE REGARDING TAR AND NICOTINE YIELDS IN CIGARETTES (2008).

For FTC guidance on tar and nicotine, see FTC, FTC to Begin Cigarette Testing,
NEWS SUMMARY (Aug. 18, 1967), http://hdl.handle.net/2027/uiug.30112104343899
[http://perma.cc/P8YT-34QR].
79 Cigarette Controls: A Sick Joke So Far, 33 CONSUMER REPS. 97, 102 (1968).
80 Id. The tar and nicotine measures were also seen as a helpful tool to dispel the
belief that filtered cigarettes were effective in reducing harmful chemicals in smoke, as
filtered cigarettes seen as healthier dominated the cigarette market. Id.
81 See Burrows, supra note 78.
82 See Jeffrey Wigand, What is the FTC Method of Cigarette Analysis?,
http://jeffreywigand.com/FTCmethod.pdf [http://perma.cc/X9MK-YTPE] (last visited Feb. 27,
2020); Burrows, supra note 78.
83 FTC ANN. REP. at 18-19, 78-79 (1967).
84 Cigarette Controls: A Sick Joke So Far, supra note 79, at 98.
85 Id.
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industry advertising. 86 The Commission expressed concern about
the impacts of advertising on teenagers who appeared to be a
prime target of television cigarette promotions. 87 Tobacco ads
depicted smoking as a relatively safe and fashionable behavior,
never pointing out the addictive nature of the product. 88 The FTC
noted that the industry did not appear to be following its own
self-regulatory guidelines-particularly evident in its promotion
of filtered cigarettes and its failure to mention the increasing
evidence of the growing health hazards linked to smoking. 89 The
Commission report recommended that package warnings be more
stringent, using language that reads, "Cigarette Smoking Is
Dangerous to Health and May Cause Death From Cancer and
Other Diseases," and that such warning be expanded from
packages to all product advertising, and mandate specific tar and
nicotine content information. 90 In addition, the FTC called for
appropriations of funds to support anti-smoking programs,
especially for children, as well as support for the development of
a "safer" cigarette. 91
The broad health concerns over cancer and environmental
pollution became legislative drivers of the 91st Congress and,
within this context, the ongoing battle over how tobacco was to
be regulated unfolded. Within the cigarette-smoking arena, the
aggressive posture of the Surgeon General and the FTC,
together with the use of the fairness doctrine mandated by the
FCC, drove government's executive branch smoking activism. A
Congressional showdown on tobacco in 1969 was sparked by the
sunset provision in the FCLAA concerning warning language and
advertisement regulation. 92 Numerous tobacco bills were
introduced in the U.S. House of Representatives in 1969 that
posited several primary approaches for ongoing regulation,
including a stronger warning label, the inclusion of tar and
nicotine levels on packaging and advertisements, prohibition of
broadcast cigarette ads, as well as extension of provisions of the
1965 FCLAA. 93 During the time period the 91st Congress was
deliberating new cigarette legislation, the FCC began
rule-making processes to ban the broadcast of cigarette ads on

86 See id.
87

Id.

88 See id. at 98, 100.
89 See id. at 100.
90 Id.
91 See id.
92 See S. REP. NO. 91-566, at 1-2 (1969), as reprinted in 1970 U.S.C.C.A.N. 2652,
2652-53.
93 Edward Klebe, CONG. RESEARCH SERV., 79-219EPW, ACTIONS OF THE CONGRESS
AND THE FEDERAL GOVERNMENT ON SMOKING AND HEALTH 19-24 (1979).
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radio and television and the FTC announced an even more
stringent package warning than had been suggested in its 1967
Report to Congress. 94 In the Senate, the focus of their tobacco
hearings was centered on industry self-regulation. 95 As a result of
regulatory pressure and the growing impacts of the fairness
doctrine pressure, the tobacco industry voluntarily offered to
discontinue broadcast advertising-a strategic move to mitigate
other legislative initiatives. 96 In turn, the FTC offered to suspend
its efforts to require health warnings in cigarette advertisements
97
until 1971 if broadcasters voluntarily withdrew cigarette ads.
After a long process of hearings and debate, the 91st
Congress enacted the second major piece of federal tobacco
legislation: the PHCSA of 1969.98 The legislation contained five
key parts: (1) the suspension of broadcast media cigarette
advertising; (2) a change in package label warnings; (3) a
prohibition on state and local government regulation of tobacco
advertising; (4) the suspension of FTC action on print advertising
until July 1, 1971; and (5) a requirement that the FTC and
DHEW report annually to Congress on the consequences of
smoking, the effectiveness of labeling, and advertising
practices. 99 While the PHCSA was somewhat more rigorous than
the FCLAA, the final bill was the product of significant
compromise and was, no doubt, heavily influenced by the strong
hand of the tobacco lobby. 10 0 As was the case with the FCLAA,
the White House appeared to distance itself from the PHCSA.
The strong support from the public health community, and the
drive to eradicate cancer that led to the National Cancer Act in
the following year, marked a political climate that resulted in
President Nixon signing the new cigarette act on April 1, 1970.101
On January 1, 1971 at 11:50 p.m., the last cigarette ad ran
on network television, as what was arguably the most significant
provision of the PHCSA of 1969 went into effect.10 2 Television
cigarette advertising was a hallmark of broadcast media, and

94 See id. at 21.
95 Id. at 23.
96 See id.
97 Id. at 24.
98 Public Health Cigarette Smoking Act of 1969, Pub. L. No. 91-222, 84 Stat. 87
(codified as amended at 15 U.S.C. §§ 1331-1340 (2012)).
99 See id. at 87-89.
ioo NAT'L COMMN ON MARIHUANA & DRUG ABUSE, supra note 11, at 525.
ioi ANNA D. BARKER & HAMILTON JORDAN, Legislative History of the National Cancer

Program, in HOLLAND-FREI CANCER MEDICINE (Donald W. Kufe et al. eds., 6th ed. 2003),
http://www.ncbi.nlm.nih.gov/books/NBK13873/ [http://perma.cc/K2XB-FESB].
102 Nixon signs legislation banning cigarette ads on TV and radio, HISTORY,
http://www.history.com/this-day-in-history/nixon-signs-legislation-banning-cigarette-ads-ontv-and-radio [http://perma.cc/9JZ3-DH4U] (last updated July 28, 2019).
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was seen as a major influence on children. 10 3 In 1970, their final
year on the airwaves, tobacco manufacturers spent over $200
million on TV ads. 10 4 But even prior to the U.S. ad ban, strict
regulation of broadcast tobacco ads in several European
countries, and an outright prohibition in the UK, appeared to
10 5
have little impact on smoking rates in those countries.
Curiously, with the ban on cigarette advertising in place, the
FCC mandate to require broadcasters to run free public health
anti-smoking ads was no longer necessary, thereby abrogating
the use of the fairness doctrine.1 06 While television ads were
eliminated, tobacco manufacturers continued their vigorous
marketing elsewhere.10 7 They shifted to print media and point of
10 8
sale promotions, as well as various types of product sponsorships.
Broadcasters, on the other hand, were faced with significant
revenue losses and challenged the PHCSA ad ban in court, as
being in violation of First Amendment commercial speech
protections, and Fifth Amendment due process rights. 10 9 A three
judge panel in Capital Broadcasting Co. v. Mitchell disagreed
with the broadcasters' legal claims and ruled that commercial
speech protections were more limited than other forms of
speech.1 10 Congress had the power to ban broadcast media
cigarette advertising based on either its authority over
regulatory agencies or interstate commerce. The court in Mitchell
found that the broadcasters' rights to free speech were not
violated, as their revenue loss from cigarette ads did not prohibit
them from commenting on the issue of smoking and public
health. 1 In a dissenting opinion in Mitchell, Judge Skelly
Wright argued that the ban on cigarette advertising was a
matter of public importance that should receive full
constitutional speech protections.1 1 2 Judge Wright was
particularly concerned that the ban on TV and radio advertising
took the issue off the airwaves and, in so doing, denied the use of
the fairness doctrine to spark a more balanced discussion of the
11 3
health impacts of cigarettes.
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http://www.washingtonpost.com/archive/pohtis/1979/O1/15/cigarette-advertising/a4e78bd-85e14d2a-90dl-eOcbc4c7b8fd/?noredirect&utmterm=.074621ddf~f7 [http://perma.cc/EGQ9-XSJB].
104 Id.
105 See BRANDT, supra note 23, at 271.

106 See id. at 271-72.
107 See id. at 272.
108 See id.
109 Capital Broad. Co. v. Mitchell, 333 F. Supp. 582, 583 (D.D.C. 1971).
110 See id. at 583, 585-86.
in1 See id. at 586.
112 See id. at 587 (Wright, J., dissenting).
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The package warning label requirement in the PHCSA was
not a novel legislative provision as the cigarette ad ban was, but
rather offered a modest extension of the warning requirement in
the FCLAA, with the inclusion of language that added the
gravitas of the U.S. Surgeon General to the package label. The
original 1965 warning label requirement did not succeed in
reducing cigarette consumption, but rather than abandoning the
idea of a consumer warning, subsequent legislative initiatives,
starting with the 1969 PHCSA, amended the mandatory language
to make the warnings more detailed. 114 The PHCSA prohibited the
FTC from requiring the cigarette warnings apply beyond package
labels, but that limitation was only in place until July 1, 1971, and
once this moratorium had expired, the Commission, which was
strongly committed to use of consumer warnings,
expanded the
11 5
requirement to include all tobacco advertising.
The use of a product warning has a dual objective of both
educating the public about the risks posed by a given product, as
well as deterring use of the product. Clearly the goal of use
deterrence was not one that was welcomed by cigarette
manufacturers and sellers, and so the industry struggled to meet
the legal warning requirements in ways that minimized their
impact on sales. On the government side, even with ongoing
mitigation efforts, there was no centralized voice for tobacco
control in either the Executive branch or Congress.1 16 Pockets of
strong opposition to regulation were sparked by pressure from
heavy lobbying by tobacco manufacturers and agricultural
interests.1 17 The cigarette warning label requirement in the
PHCSA demonstrated underlying tensions in government
ranks.1 1 8 The regulators in the Executive branch were strong
supporters of comprehensive oversight, in opposition to views
sparked by economic concerns in Congress and the White House
that resulted in favoring more limited approaches to cigarette
regulation, including minimal package warnings.11 9
As previously noted, during the Nixon Administration,
Surgeon General Steinfeld was an ardent anti-tobacco advocate,
and specific to tobacco warnings, his views aligned with the
FTC's position for much more stringent oversight than what was

114 See Public Health Cigarette Smoking Act of 1969, Pub. L. No. 91-222, 84 Stat. 87,
88 (1970).
115 See Klebe, supra note 93, at 29.
116 See BRANDT, supra note 23, at 277.
117 See id.
118 See Memorandum for the Att'y Gen., supra note 69, at 1-6.
119 See id.
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legislated in the PHCSA. 120 On the other hand, as evidenced in a
1972 Republican memorandum to the attorney general on
tobacco regulation, concerns were voiced about anti-smoking
measures that were having a negative impact on political support
for President Nixon in southern states. 12 1 In the noted
memorandum, the tobacco industry was praised for its
willingness to self-regulate and pursue objective scientific
research into the health aspects of cigarettes. 122 Surgeon General
Steinfeld was characterized as an anti-smoking zealot with a
vendetta against tobacco that was pursued at the expense of
dealing with other hazardous substances. 123 The warning
provision in the PHCSA balances countervailing pressures, as
the package label requirement was driven by a regulatory
commitment to educate the public about the hazards of smoking,
a culture of individualism,
and a strong desire not to disrupt the
124
economic status quo.
In his 1968 presidential campaign, President Nixon was
asked about his opinion on tobacco warnings. The President
characterized the studies concerning smoking and health as
controversial, and noted that all the federal government could do
concerning cigarettes was provide information about smoking
hazards to the public, and let individuals choose. 125 He expressed
skepticism about whether warnings would have any impact on
consumer behavior. 126 Like the prior Kennedy and Johnson
administrations, the Nixon White House was very guarded in its
support of anti-smoking measures, and while Nixon signed the
PHCSA into law, no fanfare accompanied this signing.127
IV. BEYOND THE PHCSA: THE TRAJECTORY OF WARNINGS
At first blush, it appears that the legacy of the PHCSA sinks
into the sea of laws, regulations, and litigation that developed in
the area of tobacco control since 1970. Still, the major
components of the 1969 law-the advertising ban, revised
warning labels, and preemption of local/state law on
advertising-were significant steps in the history of tobacco use
abatement measures that remain relevant in the current
smoking landscape. Indeed, as the smoking question has

120 See Snyder, supra note 66, at 1258.
121 Memorandum for the Att'y Gen., supra note 69, at 1.
122 Id. at 4-5.
123 Id. at 1-2.
124 See id. at 1-6.

125 Id. at Attachment A.
126 Id.

127 See Nixon signs legislation banningcigarette ads on TVand radio, supra note 102.
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expanded into new and different forms of nicotine delivery
devices beyond traditional cigarettes, the fundamental and
long-standing regulatory controls found in the PHCSA remain
viable public health tools in the face of the growing use of
e-cigarettes and a heightened awareness of the need to control
health care costs through more effective prevention.
There are three developments post-1969 concerning smoking
mitigation that should be noted in tracking the evolution of
tobacco regulation, dealing directly and indirectly with warning
labels. First, from the mid-1970s, a major catalyst for ongoing
smoking regulation was the growing public concern over the
dangers of cigarette smoking, fueled by an awareness of the
impacts of secondhand smoke. 128 With the emergence of solid
evidence that non-smokers exposed to cigarette smoke were at
risk for numerous medical conditions, the public health focus
over smoking broadened. 129 Smoking abatement was no longer
limited to concerns about individual behavior that centered on
questions of personal choice, but expanded into a population wide
problem.130 Numerous laws enacted, at all levels of government,
prohibited smoking in various indoor and outdoor spaces.13 1 With
13 2
them came ubiquitous signage declaring no smoking policies.
There was also a growing awareness and concern about nicotine
content in cigarettes, as science emerged that cautioned about
13 3
the addictive nature of this chemical.
A second development that affected the direction of warnings
occurred in 1972 when cigarettes and other tobacco products
were excluded from the jurisdiction of the Consumer Products
Safety Commission ("CPSC"), thereby closing an avenue for
possibly more impactful regulation by another regulatory
actor.1 3 4 In 1973, a request was made to the CPSC to set a
maximum level of twenty-one milligrams of tar in cigarettes and
ban any cigarettes exceeding that amount from interstate
commerce, drawing on the Federal Hazardous Substances Act

128 See BRANDT, supra note 23, at 292-93.
129 See
Melissa
Conrad
Stoppler,
Secondhand Smoke,
MEDICINENET,
http://www.medicinenet.com/secondhand-smoke/article.htm#secondhand-smoke-facts
[http://perma.cc/JC5Q-4DVA] (last updated Nov. 13, 2018).
130 See id.
131 See Dustin Heap, No Smoking Laws For All Fifty States, SIGNS.COM (May 20, 2014),
http://www.signs.com/blog/no-smoking-laws-for-all-fifty-states/ [http://perma.cc/H5TH-YRKS].
132 See id.
133 See U.S. DEP'T OF HEALTH & HUMAN SERVS., THE HEALTH CONSEQUENCES OF
SMOKING: NICOTINE ADDICTION: A REPORT OF THE SURGEON GENERAL 6 (1988),

http://profiles.nlm.nih.gov/spotlight/nn/catalog/nlm:nlmuid- 10 1584932X426-doc
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134 Consumer Product Safety Act, Pub. L. No. 92-573, 86 Stat. 1207, 1207-08 (1972).
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("FHSA") as supporting law. 135 According to the General
Accounting Office ("GAO"), who had been referred the matter by
the U.S. Comptroller General, the FHSA did not extend to
cigarettes, and while the CPSC could regulate matters under the
FHSA generally, tobacco oversight was limited to Congress. 136
Concern about CPSC regulation was great enough to result in
legislative action that explicitly excluded tobacco regulation from
the FHSA. 137 In addition, tobacco was further excluded from
inclusion in both the Controlled Substances Act ("CSA"), as well
as the Toxic Substances Control Act ("TSCA"), in essence leaving
cigarettes exempt from the oversight of
significant consumer and
138
worker protection regulatory schemes.
A third major development in tobacco control can be found in
the evolution of smoking litigation that escalated throughout the
second half of the twentieth century. Often, liability claims at
state levels raised questions about the impacts of mandated
warning labels; but, starting with the FCLAA, such state claims
were preempted, spawning a reliance on alternative causes of
action. 139 It would take several decades, but eventually
consolidated tobacco litigation culminated in a master settlement
between states' attorney generals in 1998.140 The settlement
resulted in historic payments by the manufacturers to individual
states and adoption of an array of measures, particularly
oriented to youth, that restricted cigarette advertising and
marketing, as well as prohibited industry practices designed to
hide health information about the dangers of smoking.141
While the cigarette smoking challenge continued to spark
new approaches to regulation, the use of warning labels that
came out of the FCLAA and the PHCSA in the 1960s was not
abandoned, even in the face of skepticism about the effectiveness
of warnings on education and prevention. 142 A review of the
135 Klebe, supra note 93, at 33-34.
136 Id. at 34-35. The Consumer Products Safety Commission validated the
conclusions of the GAO concerning the Federal Hazardous Substances Act in a three to
two vote on May 17, 1974 that the Commission lacked the authority to regulate tar in
cigarettes. Id. at 35.
137James T. O'Reilly, A Consistent Ethic of Safety Regulation: The Case for Improving
Regulation of Tobacco Products, 3 ADMIN. L.J. 215, 245 (1989). See also 15 U.S.C. § 1262(f)(2).
138O'Reilly, supra note 137, at 230.
139 See Controlled Substances Act, 21 U.S.C. § 802 (1982 & Supp. V 1987); Toxic
Substances Controlled Act, 15 U.S.C. § 2602 (1988). These statutes can serve as
alternative causes of action.
140 See The Master Settlement Agreement: An Overview, PUB. HEALTH L. CTR. (Jan.
2019), http://www.publichealthlawcenter.org/sites/default/f"iles/resources/MSA-Overview2019.pdf [http ://perma.cc/6WGG-VCFP].
141 See id.
142 See Deborah M. Scharf & William G. Shadel, Graphic Warning Labels on
Cigarettes Are Scary, but Do They Work?, RAND CORP. (Sept. 30, 2014),
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legislative history of tobacco in the 1970s demonstrates that
there were ongoing efforts to strengthen warning labels in a
number of proposed federal bills, as well as a recommendation by
the FTC to expand warnings to include tar and nicotine content
in both packaging and advertising. 143 The FCLAA was amended
in 1973 to expand package-warning requirements to include little
cigars. 144 In 1981, the FTC, in a report to Congress, concluded
that the PHCSA health warning language was no longer
impactful on public knowledge and attitudes about smoking,
spurring Congress to revisit the labeling issue.1 45 In 1984, the
Comprehensive Smoking Education Act ("CSEA," also known as
the Rotational Warning Act) was passed.1 46 This law required
cigarette packages and advertising to use one of four health
warnings that included much more explicit language about the
adverse health effects of smoking.1 47 The four rotational
warnings were mandatory for not only packaging, but for all
advertisements and outdoor billboards.1 48 The 1984 statute
contained explicit details about the format of labeling, and
required that manufacturers and importers submit advertising
149
plans for approval to the FTC for each brand of cigarettes.
CSEA was an attempt to refocus cigarette control efforts, not
only by expanding warnings labels, but also by extending
anti-tobacco educational efforts, tracking cigarette ingredients,
and facilitating interagency coordination of anti-smoking
efforts.15 0 Not long after CSEA was enacted, mandatory
package
15 1
warnings were extended to smokeless tobacco products.
The rotational warnings on both cigarettes and smokeless
tobacco became a fixture on cigarette packages. Despite a
whirlwind of legal and policy developments concerning smoking
abatement, this regulatory mandate-a vestige from the
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Cause Death From Cancer, Coronary Heart Disease, Chronic Bronchitis, Pulmonary
Emphysema, or Other Diseases").
144 Little Cigar Act, Pub. L. No. 93-109, 87 Stat. 352, 352 (1973).
145 See 1981 FTC ANN. REP. 6.
146 Comprehensive Smoking Education Act, Pub. L. No. 98-474, 98 Stat. 2200,
2201-02 (1984).
147 Id.
148 Id.
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1960s-held firm. The skepticism, noted above, about the
efficacy of cigarette label warnings remained a persistent
undertone in this area. In a landmark report on tobacco control
in 2007, the Institute of Medicine (1M") voiced support for the
use of packaging as an effective vehicle for health
communications, but concluded that the warnings stemming
from CSEA were inadequate. 152 The IOM called for revised
warnings to foster greater public awareness of health risks, as
153
well as to discourage consumption.
The 2007 IOM report was a harbinger of the Family
Smoking Prevention and Tobacco Control Act of 2009 ("TCA"),
the most comprehensive federal legislation in the tobacco
control area to date.1 54 Congress crafted the TCA based on key
evidence drawn over several decades.1 55 Major drivers of the law
included reducing smoking among children and adolescents,
recognizing the strong link between smoking and addiction to
nicotine, and continuing public educational efforts to counter
tobacco-marketing efforts.1 56 The TCA established a broad
framework for ongoing regulation-drawing together in one bill
an array of measures posited for some time.1 57 In particular, the
law designated the federal Food and Drug Administration
("FDA") as the central authority in this area, giving the
Administration the power to regulate the manufacture,
distribution, and marketing of cigarettes, cigarette tobacco,
roll-your-own tobacco, smokeless tobacco, and any other tobacco
product the Administration deems by regulation to be considered
a "tobacco product." 158 The 2009 law provides three pathways for
approval of new tobacco products by the FDA in conjunction with
its general powers under the Food, Drug, and Cosmetic Act.1 59 The
three regulatory pathways include a pre-market approval order for
all new tobacco products; secondly, a modified risk tobacco product

152 See INST. OF MED., ENDING THE TOBACCO PROBLEM: A BLUEPRINT FOR THE NATION

289-96 (Richard J. Bonnie et al. eds., 2007).
153 See id.
154 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123
Stat. 1776 (2009).
155 See id. at 1777-81.
156 See Nicopure Labs, L.L.C. v. FDA, 266 F. Supp. 3d 360, 371 (D.C. Cir. 2017).
157 See Family Smoking Prevention and Tobacco Control Act An Overview, U.S. FOOD
& DRUG ADMIN.,
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updated Jan. 17, 2018).
158 See Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (1938) (codified
as amended in scattered sections of 21 U.S.C.); see also Deeming Tobacco Products to be
Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking
Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco
Products, 79 Fed. Reg. 23,142, 23,142 (2014).
159 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 387j, 387k (2012).
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category that applies to single products that have been altered to
modify health considerations; and thirdly, a substantial
equivalence plan for predicate products that came on the market
prior to March 2011.160 It is noteworthy that tobacco products that
were unchanged since entering the market prior to 2007-while
subject to FDA regulation-are treated as grandfathered brands,
not requiring specific Administration approval. 16 1 Another
noteworthy feature of the Act is the requirement that cigarette
companies disclose all product ingredients, and stop using
descriptive words like "light" and "ultra-light" to create the
impression that a particular product is a healthy smoking
alternative.16 2 Critics of the TCA voiced concern that the
legislation comes up short.16 3 For example, it allows the FDA to
mandate lower nicotine levels in cigarettes, but by not banning
this chemical outright, it results in addicted smokers inhaling
more deeply and increased consumption by these smokers to feed
16 4
their nicotine craving.
Perhaps the most significant feature of the TCA is that the
law, for the first time in twenty-five years, imposes new labels
and warnings on tobacco packages and on advertisements. 16 5 The
combined influence of the IOM report's critique of warnings,
along with the adoption of more detailed textual warnings, and
startling graphic depictions of illnesses caused by smoking in
countries across the globe, spurred a renewed American
regulatory effort to invigorate the warning process. The 2006
World Health Organization ("WHO") Framework Convention on
Tobacco Control ("FCTC") called for the use of packaging
warnings that are rotating, "large, clear, visible and legible,"

160 See Premarket Tobacco Product Applications, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/premarkettobacco-product-applications [http://perma.cc/RQ8K-KJX6] (last updated Oct. 25, 2019);
Modified Risk Tobacco Products, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/tobaccoproducts/advertising-and-promotion/modified-risk-tobacco-products [http://perma.cc/9746TVYP] (last updated Oct. 22, 2019); FOOD & DRUG ADMIN., DEMONSTRATING THE
SUBSTANTIAL EQUIVALENCE OF A NEW TOBACCO PRODUCT: RESPONSES TO FREQUENTLY

ASKED QUESTIONS (3d ed. Dec. 2016), http://www.fda.gov/media/90811/download
[http://perma.cc/E76U-D22D].
161 For an interesting discussion of the deeming rule, see Introducing the FDA
Deeming Authority ClarificationAct of 2015, 114th Cong. 5694 (Apr. 28, 2015) (statement
of Hon. Tom Cole).
162 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123
Stat. 1776, 1780 (2009).
163 Michael Siegel, Tobacco regulations are no regulations at all, L.A. TIMES (June 3,
2009), http://web.archive.org/web/20 1612260 15412/http://articles.latimes.com/2009/jun/03/
opinion/oe-siegel3 [http://perma.cc/7JW7-K79Y].
164 Id.
165 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123
Stat. 1776, 1842-43.
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and includes pictures or pictograms. 16 6 Under the TCA, the FDA
was empowered to require that cigarette packages and
advertisements bear one of nine new health warnings and that
the warnings, with graphics, comprise 50% of the front and rear
panels of cigarette packages. 16 7 The new label warnings are
linked to the FDA requirements under the Administration's
misbranding provisions, which require that a regulated product
include proper labeling.1 68 In the case of cigarettes, the product
would be considered misbranded if it failed to comport with the9
16
necessary language, placement, typography, and graphics.
Congress legislated the nine rotational warnings that were to be
used, but left the selection of accompanying graphics in the
hands of the FDA.170 The law allows the FDA to adjust the type
size, text, and format of cigarette health warnings to ensure that
the graphics and accompanying text are clear, conspicuous,
legible, and adequately sized. 171
In deciding which graphic warnings to be used, the FDA
was tasked with balancing a strategy to discourage nonsmokers,
especially children, from initiating cigarette use and to
encourage current smokers to change their behavior in order to
reduce health risks.1 72 The Administration analyzed thirty-six
graphic images drawn from consumer research on health
communications,
considering
cognitive
and
emotional
reactions.1 73 The FDA concluded that risk information was best
communicated through emotional messages, because such
1 74
messages are more likely to garner a reaction from smokers.
The Administration settled on nine graphic images to accompany
each of the new mandated warning statements, together with a
phone number from the National Cancer Institute's "Network of
Tobacco Cessation Quitlines."1 75 Selection of the graphic images
was based on an 18,000-person Internet survey that focused on

166 WORLD HEALTH ORG., WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL, Art.

11.1(b) (Feb. 27, 2005).
167 15 U.S.C. § 1333 (2012) (The warnings include: "[c]igarettes are addictive"; [t]obacco
smoke can harm your children"; [c]igarettes cause fatal lung disease"; "[c]igarettes cause
cancer"; [c]igarettes cause strokes and heart disease"; "[s]moking during pregnancy can
harm your baby"; "[s]moking can kill you"; "[t]obacco smoke causes fatal lung disease in
nonsmokers"; and "[q]uitting smoking now greatly reduces serious risks to your health").
168 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 387c (2012).
169 See id. § 321(n).
170 See 15 U.S.C. § 1333.
171

See id.

See Required Packaging Warnings for Cigarette Packages and Advertisements,
75 Fed. Reg. 69,525 (Nov. 12, 2010).
173 See Required Warnings for Cigarette Packages and Advertisements, 76 Fed. Reg.
36,637-38 (June 11, 2011).
174 Id. at 36,639.
175 Id. at 36,681.
172
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whether the proposed graphic increased the consumer's desire to
quit or refrain from smoking, expanded knowledge about the
risks of smoking and secondhand smoke, and sparked a negative
reaction. 176 In its response to criticisms about the new graphic
labels, the FDA acknowledged that its study did not permit the
Administration to reach firm conclusions about long-term effects
of the proposed warnings, but justified the new regulation based
on scientific literature and the177 widespread use of graphic
warning labels in other countries.
Following the issuance of the final rule implementing the
FDA's new graphic cigarette package warnings, the tobacco
companies filed two separate lawsuits. In a suit brought in the
Western District of Kentucky in Discount Tobacco & Lottery
v. United States, five tobacco companies and one retailer
challenged the legality of the 2009 Tobacco Control Act on
several grounds. 178 One such ground claimed that the new
labeling requirements violated commercial speech rights under
the First Amendment. 179 In overturning a district court grant of
summary judgment to the corporate plaintiffs resting on the use
of a First Amendment strict scrutiny standard, the court of
appeals in the Kentucky case applied a more liberal approach to
commercial speech that rested on the state's interest in
preventing consumer deception. 180 The court found that the new
graphic warnings constituted a form of commercial speech that
was accurate, salient, and reasonably related to health
protection. 18 1 Further, it found that the labeling requirement did
not infringe on the plaintiffs' speech rights, as either an undue
18 2
burden or an unjustified consumer protection.
Another suit was filed by the tobacco industry that
challenged the legality of the FDA graphic warning label
regulation, rather than the statutory challenge against the TCA
176 See id. at 36,637.
177 R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 1210 (D.C. Cir. 2012), overruled on
othergrounds by Am. Meat Inst. v. U.S. Dep't of Agric., 760 F.3d 18, 22-23 (D.C. Cir. 2014).
178 Disc. Tobacco City & Lottery, Inc. v. United States, 674 F.3d 509, 518 (6th Cir. 2012).
179 Id.
180 See id. at 522. The court relied on the commercial speech test articulated by the
U.S. Supreme Court in Zauderer v. Office of Disciplinary Counsel of Supreme Court of
Ohio. Id. at 523-24 (citing 471 U.S. 626, 627 (1985)).
181 See id. at 522-23, 531.
182 See id. at 530-31. The court of appeals found that the requirement to include a
'quit" number on cigarette labels did not fall under the Zauderer standard but should be
subjected to a more stringent standard of review as it was not designed to directly inform
consumers, but rather constitutes a smoking mitigation measure. See id. at 522-23.
Under the more rigorous Central Hudson test, the "quit" number needed greater
justification to demonstrate it is the most viable mechanism to meet a government goal;
on its face, the "quit" number contradicts the tobacco company message at the point of
sale, imposing a significant burden on commercial speech. See id. at 522-23, 544.
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raised in Discount Tobacco & Lottery. The corporate plaintiffs in
the D.C. circuit case of R.J. Reynolds v. FDA argued that the
graphic warning regulation infringed on their First Amendment
commercial speech rights. 183 Unlike the court in Discount
Tobacco & Lottery, the R.J. Reynolds court applied a First
Amendment review based on precedents from Zauderer v. Office
of Disciplinary Counsel of Supreme Court of Ohio, and a more
challenging commercial speech analysis drawn from the case of
84
Central Hudson Gas & Electric v. Public Service Commission.
The D.C. court reasoned that purely factual and uncontroversial
required disclosures per Zauderer were allowed under the First
Amendment, provided such disclosures were justified and not
overly burdensome.1 85 The court's analysis next included the
application of elements drawn from Central Hudson, which
required that in order to restrain free speech, the government
must demonstrate a valid interest, the advancement of that
interest in its exertion of regulatory authority, and a showing that
the regulation in question was narrowly cast.18 6 The D.C. court
concluded that the FDA failed to present any data that enacting
the proposed graphic warnings would accomplish the objectives of
reducing smoking rates.1 87 The court found that consumers could
misinterpret some of the required images, and that others failed to
convey any warning language at all.1 88 The R.J. Reynolds court
vacated the rule and remanded it back to the Administration.
Following the decision, the FDA withdrew the graphic warning
rule, even though, as noted, the Western District of Kentucky had
supported the constitutionality of the TCA. 189 Shortly after the
D.C. decision, the Attorney General of the United States notified
Congress that the FDA would undertake research to support a
new rulemaking effort consistent with the Tobacco Control Act.1 90
In the interim, the warning label requirements that required a
textual warning-which had been in place since 1984-remained
in force.
The FDA moved very slowly in developing a new
tobacco-labeling rule, even in the face of its statutory obligation

183 See R.J. Reynolds, 696 F.3d at 1211.
184 See id. at 1217.
185 See id. at 1216.
186 See id. at 1217.
187 Id. at 1219.
188 See id. at 1216-17.
189 See id. at 1222.
190 Letter from Eric Holder Jr., Att'y Gen., to the Honorable John Boehner, Speaker,
U.S. H.R. (Mar. 15, 2013) (on file with the Univ. of Cal. S.F. Ctr. for Tobacco Control Res.
& Educ.), http://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Ltr /%20to/%2OSpeaker/%20
re%20Reynolds%20v%20FDA.PDF [http://perma.cc/6HDL-QF7N].
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under the TCA and a 2012 court decision compelling action in this
area. 191 Frustration with Administration inaction on the part of
public health advocates resulted in a legal challenge in the United
States District Court for the District of Massachusetts, which
alleged that the Administration was unlawfully withholding action
in its failings to issue new graphic warning labels.19 2 The action
193
sought a court order to compel rulemaking.
The Massachusetts Federal District Court in American
Pediatrics v. FDA ruled in favor of the plaintiff health care
associations, holding that the Administration unlawfully
withheld and unreasonably delayed issuing graphic warning
labels.19 4 The court found that the Administration failed to justify
its delay in the face of public health and welfare interests, and
absent a showing of competing priorities.19 5 The judge ordered
the FDA to issue a new proposed rule on graphic cigarette
warnings in compliance with the TCA by August 15, 2019, with a
final rule to be completed by March 15, 2020.196
In August of 2019, eight years after the first notice of
proposed rulemaking was issued to implement the graphic
warning provisions of the TCA, the FDA issued a new proposed
rule in compliance with the federal court order in American
Pediatrics.19 7 The Administration proposed thirteen new textual
health warning label statements "accompanied by color graphics
depicting the negative health consequences of smoking."19 8 These
new color graphics are required to "appear prominently on
packages and in advertisements, occupying the top 50 percent of
the area of the front and rear panels of cigarette packages and at
least 20 percent of the area at the top of cigarette
advertisements." 199 The warnings and graphics focus on
well-known health risks caused by smoking, such as lung cancer
and heart disease, but also include lesser-known risks, like

191 See R.J. Reynolds, 696 F.3d at 1222.
192 Court Orders FDA to Issue Proposed Graphic Cigarette Warning Rule This Year,
TROUTMAN SANDERS: TOBACCO L. BLOG (Apr. 24, 2019), http://www.tobaccolawblog.com/
20 19/04/court-orders-fda-to-is sue-proposed-graphic-cigarette-warnings-rule-this-year/
[http://perma.cc/BRR7-UF8G].
193 Id.
194 Am. Acad. of Pediatrics v. FDA, 330 F. Supp. 3d 657, 667 (D. Mass. 2018).
195 Id.

196 Federal court orders FDA to issue final rule requiringgraphic cigarette warnings, TRUTH
INITIATIVE (Mar. 6, 2019), http://www.truthinitiative.org/press/ress-release/federal-court-ordersfda-issue-final-rule-requiring-graphic-cigarette-warnings [http://perma.cc/N555-EW4Y].
197 See Tobacco
Products; Required Warnings for Cigarette Packages and
Advertisements, 84 Fed. Reg. 42,754, 42,754 (Aug. 16, 2019).
198 Id. at 42,757.

199 Id.
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bladder cancer and diabetes. 20 0 The FDA developed the new rule
in the wake of the R.J. Reynolds case, so the commercial speech
elements in Zauderer and Central Hudson became essential
parameters in the development of the rulemaking process. 20 1 The
new rule, driven by the court critiques in R.J. Reynolds, was the
product of extensive legal, scientific, and regulatory analysis
resting on an iterative research process that was much more
detailed than the case made for the 2011 rule. 20 2 The FDA
regulators posit that the new rule advances a substantial
government interest and is no more extensive than is
necessary. 20 3 The Administration believes that its original and
expansive research provides a basis for the revised cigarette
warnings that offer consumers' new information, sparking
greater understanding about the health risks of smoking, and is
both more understandable and memorable than prior Surgeon
General warnings. 20 4 In addition, the FDA was very conscious of
not mandating warnings that are purely emotional in character,
but rather took pains to develop labels which simultaneously
garner attention and convey substantive messages. 20 5 Under the
dictates of the proposed rule, product manufacturers, distributors,
and retailers must submit a plan to the FDA for the random
display and distribution of required warnings on packages. 206 The
thirteen new warning labels and the twelve accompanying
picture graphics are set to take effect fifteen months after the
final FDA warning label regulation is in place, which may occur
in 2021.207 It is conceivable that a new commercial speech
challenge may be mounted, as the tobacco industry is unlikely to
cede the marketing benefits of its packaging without a fight.
V. WARNINGS AND THE DEEMING RULE
While most of the developments concerning tobacco
warnings, dating back to the 1970s' FCLAA and PHCSA, center
on cigarette packages and advertisements, such mandates also
extend to other tobacco products and were motivated by evolving
health concerns. As noted earlier, special textual warning
requirements for smokeless tobacco products have been in place

200 See id. at 42,773-76.
201 See id. at 42,778-79.
202 See id. at 42,778.
203 See id. at 42,777-79.
204 See id. at 42,772.
205 See id. at 42,778.
206 Id. at 42,755.
207 See id. at 42,784.
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since 1986.208 In a 2000 FTC settlement, the seven largest
American cigar manufacturers agreed to include health warnings
on packaging and in advertisements.20 9 The settlement led to the
adoption of one of five textual cigar-smoking warnings.2 10 The
most significant expansion of tobacco product warning label
requirements emerges from the 2009 TCA. Under the TCA, the
FDA is granted authority to regulate all tobacco products which
includes cigarettes, cigarette tobacco, roll-your-own tobacco,
smokeless tobacco, and, very significantly, any other product it
deems, by regulation, to be a tobacco product.2 11 The FDA under
its "deeming" authority is able to apply a very broad definition of
what a tobacco product is, including "any product made or
derived from tobacco ... including any component, part, or
accessory of a tobacco product .. .. *"212 To date, the expanded
regulatory power includes electronic nicotine delivery systems
2 13
(e-cigarettes and e-liquid), cigars, hookah, and pipe tobacco.
The TCA scheme allows tobacco products that were on the market
prior to 2007 to continue being sold without Administration
approval, but other tobacco products are subject to regulation,
either as equivalent to pre-2007 smoking implements
or ones that
2 14
must obtain a new tobacco marketing order.
In May 2016, under the auspices of the TCA, the FDA
issued a final deeming rule that established a regulatory floor
for control of so-called "other tobacco products" ("OTP"), with 15
a
2
particular emphasis on electronic nicotine delivery systems.
Under the deeming rule, the Administration may use its power
to restrict the sale, distribution, and promotion of OTPs,
provided such actions are for public health purposes.2 16 A key
feature of this final rule is its focus on the issue of warning

208 See Comprehensive Smokeless Tobacco Health Education Act of 1986, Pub. L. No.
99-252, 100 Stat. 30 (codified as amended at 15 U.S.C. §§ 4401-4406, 4408 (2012)). This
law requires smokeless tobacco product packages and advertisements to include health
related warning labels on a rotational basis. Id. at 31-32.
209 FTC Announces Settlements Requiring Disclosure of Cigar Health Risks, FTC
(June 26, 2000), http://www.ftc.gov/news-events/press-releases/2000/06/ftc-announcessettlements-requiring-disclosure-cigar-health-risks [http://perma.cc/S9XY-8KZ3].
210 Id.

211 21 C.F.R. § 1100.1 (2019).
212 21 U.S.C. § 321(rr)(1) (2012).
213 See Deeming Tobacco Products to be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act;
Restrictions on the Sale and Distribution of Tobacco Products and Required Warning
Statements for Tobacco Products, 81 Fed. Reg. 28,974, 29,028 (May 10, 2016) (to be
codified at 21 C.F.R. pts. 1100, 1140, and 1143).
214 See 21 U.S.C. § 387j (2012).
215 Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic
Act, 81 Fed. Reg. at 28,974-75.
216 Id. at 28,975.
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labels. 2 17 The warning requirements in the rule are centered on
the dangers of nicotine, requiring language that states, "This
2 18
product contains nicotine. Nicotine is an addictive chemical."
Packaging and advertising for cigars must continue to use one
of five warnings, as well as an addictiveness warning. 21 9 Under
the deeming rule, health warnings need to appear on at least
30% of each of the two principal
display panels of packaging or
220
20% of print advertisements.
In its notice of proposed rulemaking for the deeming rule,
the FDA makes a detailed case in support of tobacco health
warnings in both packaging and advertisements, to assist
current and future smokers in understanding the serious adverse
health consequences of smoking. 221 The Administration voices
concerns it has about consumers' erroneous and unsubstantiated
beliefs that tobacco products, other than cigarettes, are less
addictive or not addictive at all. 222 According to the
Administration, warnings ought to be directed to adolescents,
whose lack of knowledge about the risks of cigarettes and other
tobacco products, particularly e-cigarettes, make them very
susceptible to resultant health risks. 223 The FDA strategy
encompasses OTPs, which pose novel and unfolding health risks,
as the products have changed in the short time since their

introduction into the market in

2007.224

The Administration's

support of package warnings rests on the frequency of exposure
to such messages, as warnings are present at the point of
purchase, time of use, and impacts are likely to extend beyond
vapers to the public at large. 225 Formatting of warning labels and
ads is a major issue for the Administration, as research shows
that warnings that are made in small font sizes have a much

217 See id. at 28,988.
218 Id. at 28,979.
219 See FTC Announces Settlements RequiringDisclosure of Cigar Health Risks, supra
note 209. The deeming rule adopted the cigar warnings that the FTC agreed to in its 2000
settlement with manufacturers. See Deeming Tobacco Products to be Subject to the
Federal Food, Drug, and Cosmetic Act, 81 Fed. Reg. at 29061. The 2016 final rule
contained a new cigar warning directed to pregnant women, "[c]igar use while pregnant
can harm you and your baby." See id.
220 Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic
Act, as Amended by the Family Smoking Prevention and Tobacco Control Act;
Regulations on the Sale and Distribution of Tobacco Products and Required Warning
Statements for Tobacco Products, 79 Fed. Reg. 23142, 23205 (Apr. 25, 2014).
221 Id.

222
223
224
225

at 23,142.

Id. at 23,166.
See id. at 23,146.
See id. at 23,144.
Id. at 23,164.
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lower impact
on general consumer awareness than those in
226
larger font.
Cigar companies and e-cigarette manufacturers pushed back
against the deeming rule, claiming in a number of lawsuits that
the regulation was unconstitutional.2 27 As the Administrative
Procedures Act and the Regulatory Flexibility Act govern the
actions of the FDA, typically challenges against the Administration
2 28
rest on allegations of a violation of one or both statutes.
In Nicopure Labs, L.L.C. v. FDA, a Florida e-cigarette
manufacturer alleged in the District Court for the District of
Columbia that the FDA interpretation of a tobacco product that
includes e-cigarettes was too broad, and as such, not in
accordance with the Administrative Procedures Act. 229 The
e-cigarette company argued that premarket certification,
validation of health benefits, and nicotine warnings were all
unnecessary. 230 A separate challenge in the same district court
brought by eleven e-cigarette trade groups, including an
allegation that the deeming rule violated free speech rights
because of its prohibition on free sample distribution, was
consolidated with Nicopure.231 In ruling in favor of the FDA, the
district court concluded that the allegations did not concern the
details of the deeming rule, but rather focused on statutory
requirements in the TCA. 232 Under the auspices of the TCA, the
Administration had the necessary statutory authority to subject
e-cigarette and liquid manufacturers to tobacco product
regulation, and such action could not be characterized as arbitrary
and capricious. 2 33 In using the Central Hudson commercial speech
test noted earlier, the court in Nicopure found that the distribution
of free samples of e-cigarette products is not sufficiently expressive

226 See id. at 23,165. The FDA was very influenced by a 2001 European Directive
(2001/37/EC) requiring that health warnings consume 30% on the front of the packaging
and 40% on the back of the packaging. Id.
227 See Lawsuits Challenging the FDA's Deeming Rule (2019), PUB. HEALTH L. CTR.,
http://www.publichealthlawcenter.org/resources/lawsuits-challenging-fda-deeming-rule
[http://perma.cc/V9QG-U6YP] (last updated Mar. 5, 2020).
228 Administrative Procedures Act, Pub. L. No. 116-56, 60 Stat. 238 (1946) (codified as
amended in scattered sections of 5 U.S.C.); Regulatory Flexibility Act, 5 U.S.C. §§ 601-612 (2018).
229 Nicopure Labs, L.L.C. v. FDA, 266 F. Supp. 3d 360, 366, 391 (D.D.C. 2017).
230 Id. at 367-68 ("This case does not pose the question-which is better left to the
scientific community in any event-of whether e-cigarettes are more or less safe than
traditional cigarettes. The Rule did not purport to take the choice to use e-cigarettes away
from former smokers or other adult consumers; the issue is whether the FDA has the
authority to require that the choice be an informed one.").
231 Id.

at 366.

232 Id. at 368.
233 Id. at 393.
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to constitute speech, and thus the FDA has 234
the power, under the
auspices of the TCA, to restrict such conduct.
In July of 2017, the FDA announced a new comprehensive
plan for tobacco and nicotine regulation to provide a multi-year
roadmap-specifically to protect children and reduce tobacco
related disease and death. 235 The Administration's goal is to
strike a better balance between appropriate oversight of
smoking, while encouraging development of innovative tobacco
products that may be less dangerous than cigarettes. 236 As part of
its regulatory effort, the FDA rolled back the implementation of
the deeming rule to August 2021 for newly regulated tobacco
products (cigars, pipe tobacco, and hookah tobacco) and to August
2022 for non-combustible products ("END"). 237 As a result of
litigation challenging the FDA rollback, the new tobacco product
applications deadline was accelerated to 2020.238 In 2018, the
Administration issued three advanced notices of proposed
rulemaking ("ANPR") dealing with nicotine levels, regulation of
flavors, and regulation of premium cigars. 239 In the case of cigars,
the ANPR solicited ideas about how current product warnings
can be strengthened by adding any additional or alternative
language. 240 A major focus of the ANPRs concerns the FDA's
interest in establishing maximum nicotine levels that would
make tobacco products less addictive, or even non-addictive,
demonstrating that future tobacco abatement
efforts will center
241
on combating long-term product dependence.

Id. at 411.
235 FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related
disease, death, U.S. FOOD & DRUG ADMIN. (July 27, 2017), http://www.fda.gov/newsevents/press-announcements/fda-announces-comprehensive-reguatory-planshifttrajectorytobacco-related-disease-death [http://perma.cc/DJ5H-ZA7D].
234

236 Id.
237 Id.

238 See Am. Acad. of Pediatrics v. FDA, 379 F. Supp. 3d 461, 468, 498 (D. Md. 2019),
appeal docketed, No. 19-2130 (4th Cir. Oct. 16, 2019). The original deadline of 2021 was
challenged by the Vapor Technology Association ("VT'),which filed suit on August 14,
2019, seeking to enjoin the FDA from enforcing its new deadline of 2020. See Verified
Complaint (Preliminary Injunction Requested) at 2, Vapor Tech. Ass'n v. U.S. Food
& Drug Admin., No. 5:19-cv-00330-KKC (E.D. Ky. Aug. 14, 2019). The VTA suit was
subsequently dismissed for lack of standing and causation.
239 See Tobacco Product Standard for Nicotine Level of Combusted Cigarettes, 83 Fed.
Reg. 11,818 (Mar. 16, 2018); Regulation of Flavors in Tobacco Products, 83 Fed. Reg.
12,294 (Mar. 21, 2018); Regulation of Premium Cigars, 83 Fed. Reg. 12,901 (Mar. 26, 2018).
240 See Regulation of Premium Cigars, 83 Fed. Reg. at 12,903.
241 See Tobacco Product Standard for Nicotine Level of Combusted Cigarettes, 83 Fed.
Reg. at 11,819.
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VI. WARNINGS AND VAPING

Cigarette labeling requirements are part of the universe of
increasingly ubiquitous consumer product warnings, driven both
by general product liability concerns and statutory health
mandates. 242 Since their inception in the 1960s, cigarette label
and advertisement regulations have been a core element of the
tobacco use mitigation strategy. With the emergence of OTPs
(e-cigarettes, heat not burn) in recent years, subject to the FDA's
expanded authority through the deeming rule, the issue of
product warnings arises not as a historical curiosity, but rather
as a matter of immediate policy concern. Unlike cigarettes, the
newer ENDs products use an e-liquid, varying compositions of
chemical flavorings, propylene glycol, as well as vegetable
glycerin. 243 Typically these products contain some level of
nicotine and come in a dizzying assortment of flavors. 244 OTPs
are not a single product, but are multiple devices that allow users
245
to inhale an aerosol that simulates cigarette smoke.
Proponents of e-cigarettes advocate for their use as a safer choice
than cigarettes, and promote ENDs as smoking cessation
devices. 246 Taking a page from big tobacco, e-cigarette companies
have combined clever marketing and use of sweet flavor additives
to make these products extremely popular with school-aged
children. 247 The rapid rise in adolescent vaping that may result
in a new generation of nicotine addiction-reversing progress in

242 See Thomas Whiteside, Cutting Down, NEW YORKER (Dec. 11, 1970),
http://www.newyorker.com/magazine/1970/12/19/the-fight-to-ban-smoking-ads
[http://perma.cc/K2F7-H2RG].
243 See Vaporizers,E-Cigarettes,and other Electronic NicotineDelivery Systems (ENDS),
U.S. FOOD & DRUG ADMIN. (Sept. 12, 2019), http://www.fda.gov/tobacco-products/productsingredients-components/vaporizers-e-cigarettes-and-other-electronic -nicotine -deliverysystems-ends [http://perma.cc/2PC4-MFL6].
244 But see Do E-Cigs Contain Nicotine?, VAPEMOUNTAIN.COM (Apr. 20, 2016),
http://www.vapemountain.com/news/do-e-cigs-contain-nicotine.html
[http://perma.cc/Q6JJBMVV] (noting that varying levels of nicotine are available in these products).
245 See What Do We Know About E-cigarettes?, AM.
CANCER SOC'Y,
http://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/e-cigarettes.html
[http://perma.cc/4V3A-XSH4] (last updated Sept. 26, 2019).
246 See Michael Joseph Blaha, 5 Vaping Facts You Need to Know, JOHNS HOPKINS MED.,
http://www.hopkinsmedicine.org/health/wellness-and-prevention/5-truths-you-need-to-knowabout-vaping [http://perma.cc/QU3V-KB93] (last visited Oct. 13, 2019).
247 See id. The CDC estimated that between 2011 and 2015 the use of e-cigarettes among
high school and middle school children increased by 900%. Surgeon General's Advisory on
E-cigarette

Use

Among

Youth,

CTRS.

FOR

DISEASE

CONTROL

&

PREVENTION,

http://www.cdc.gov/tobacco/basic- in ormation/e-cigarettes/surgeon-general-advisory/index.htm
[http://perma.cc/Y8UW-L5VP] (last reviewed Apr. 9, 2019). Several states are suing e-cigarette
manufacturers for targeting children through deceptive marketing practices. See Naomi Martin,
Healey files lawsuit against JUUL, alleging a campaign to lure underage teens, BOS. GLOBE,
http://www.bostonglobe.com/2020/02/12/metro/ag-files-lawsuit-against-juul-alleging-campaignlure-underage-teens/ [http://perma.cc/3A7E-ZMTT] (lastupdated Feb. 12, 2020, 12:16 PM).
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smoking abatement-is a driving force in public248 health
prevention, underpinning FDA action in the OTP arena.
This growing concern over youth vaping escalated in 2019
as the CDC reported 1,604 lung injury cases in forty-nine
states, which included thirty-four deaths in twenty-four states,
with the common denominator linking these cases being the
inhalation of vapors from ENDs products. 249 The vaping-related
hospitalizations triggered heightened government scrutiny of
e-cigarettes, led by both the FDA and the Centers for Disease
Control and Prevention ("CDC").250 A few local and state
governments, following San Francisco's lead, have placed an
outright ban on the sale of e-cigarettes in light of the mysterious
outbreaks of serious pulmonary injury. 25 1 A more common
regulatory reaction against ENDs is likely to result in
comprehensive bans on the use of flavor additives such as
menthol; both the White House and the FDA are supporting
52
flavor bans. 2

248 See id.

249 Outbreak of Lung Injury Associated with E-Cigarette Use or Vaping, Products,
CTRS.

FOR

DISEASE

CONTROL

&

PREVENTION,

http://www.cdc.gov/tobacco/basic-

information/e-cigarettes/severe-lung-diseas e.html
[http://perma.cc/HJY4-7CTF]
(last
visited Nov. 10, 2019); see also Sydney Lupkin & Anna Maria Barry-Jester, Mysterious
Vaping Lung Injuries May Have Flown Under Regulatory Radar, KAISER HEALTH NEWS
(Aug. 27, 2019), http://khn.org/news/mysterious-vaping-lung-injuries-may-have-flownunder-regulatory-radar/ [http://perma.cc/783P-PZ5T]. In October 2019, the CDC issued
new guidelines for vaping related lung injuries, classifying the condition as EVALI
(e-cigarette or vaping product use associated lung injury). See 68 Morbidity and Mortality
Weekly Report 919-27 (2019).
250 See CDC, FDA, States Continue to Investigate Severe Pulmonary Disease Among
People Who Use E-cigarettes, CTRS. FOR DISEASE CONTROL & PREVENTION (Aug. 21, 2019),

http://www.cdc.gov/media/releases/2019/sO821-cdc-fda-states-e-cigarettes.html
[http://perma.cc/A8AP-ZF3Q].
251 See Victoria Colliver, In California, Juul's problems are only beginning, POLITICO
(Sept. 17, 2019, 5:01 AM), http: //www.politico.com/story/2019/09/17/juul-cigarettes-trumpcalifornia-san-francisco-1730095 [http://perma.cc/Z2XA-MSFD]; see also CNN NEWSOURCE,
Vape store owners are suing to stop the product bans in New York and Massachusetts,NEWS
CHANNEL 5 NASHVILLE (Oct. 7, 2019,

9:58 AM),

http://www.newschannel5.com/news/

national/vape-store-owners-are-suing-to-stop-the-product-bans-in-new-york-and-massachusetts
[http://peoma.cc/E9KY-5CJN]; Vapor Technology Association Files Lawsuit Against New York
Department of Health and Public Health and Health Planning Council to Stop Ill-Considered
Flavor Ban, CISION: PR NEWSWIRE (Sept. 25, 2019), http://www.prnewswire.com/newsreleases/vapor-technology-association-files-lawsuit-against-new-york-department-of-health-andpubhc-health-and-health-planning-council-to-stop-ill-considered-flavor-ban-300925566.html
[http://perma.cc/N2VS-2K2D]; Read the Lawsuit Vape Shops Sue to Overturn Gov. Charlie
Baker's Four-Month Ban on Sale of Vaping Products, MASSLIVE (Oct. 2, 2019),
http://www.masshve.com/news/2019/10/read-the-lawsuit-vape-shops-sue-to-overturn-gov-charliebakers-four-month-ban-on-sale-of-vaping-products.html [http://perma.cc/RJ23-J4H8].
252 See Colliver, supra note 251; see also Andrew B. Meshnick et al., How FDA Can Act
On E-Cigarettes And Protect The Public Health, HEALTH AFFAIRS (Sept. 17, 2019),
http://www.healthaffairs.org/do/10.1377/hblog20190916.952475/full/
[http://perma.cc/FHZ7U4FS]. The crackdown on vaping coming from the Executive branch narrowly focuses on
reusable (rechargeable) vaping devices and does not cover cheaper disposable products
which are readily available and come in an assortment of flavors. See Matthew Perrone,FDA
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Two realities define the current public health efforts to
combat the ills of smoking and reduce the resultant addiction to
nicotine, combining to make this long-standing task a type of
double bind for regulators. On one hand, health authorities face
the ongoing challenge of traditional smoking health problems,
and even in the face of significant reduction in this behavior,
there is a seemingly intractable number of smokers who pursue
this addiction, unmoved by long standing abatement strategies.
On the other hand, public health authorities must now cope with
the development of new tobacco products.2 53 The rapid growth in
use of e-cigarettes, particularly among young people, poses new
and novel challenges for anti-smoking advocates.2 54 Recent
events underscore the lack of comprehensive scientific knowledge
about the short and long-term physiological implications of ENDs
255
use, underscoring the critical need for research in this area.
There is, however, enough evidence currently to conclude that
e-cigarettes are a nicotine delivery device that can result in
addiction and easily act as a gateway to more traditional cigarette
smoking.2 56 Compounding the challenge of e-cigarettes is their
increasing use by adult smokers as a seemingly safer alternative
to traditional cigarette 257-an idea that is being endorsed with a
dearth of evidence.2 58 The power of a global tobacco industry as it
moves into ENDs products, along with a host of new smoking
options, present formable challenges to overtaxed public health
regulators trying to keep up with the new developments and
strength of the tobacco industry.2 59 An already highly profitable

crackdown on vaping flavors has blindspot: disposables, AP NEWS (Feb. 7, 2020),
http://apnews.com/600c4aa443dde043aad6f70a0025 lfaO [http://perma.cc/H2ZE-7E8L].
253 See Ana Aceves, Vaping May Lead Teens to Adopt Smoking Habits, PBS
SOCAL (Mar. 15, 2018), http://www.pbs.org/wgbh/nova/article/vaping-teen-smokinghabit/ [http://perma.cc/JEN3-Y6XJ].
254 See id.

255 See Outbreak ofLung DiseaseAssociated with the Use of E-Cigarette, or Vaping Products,
CTR. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/ basic-infomation/e-

cigarettes/severe-lung-disease.htmI [http://perma.cc/HJY4-7CTF] (last visited Oct. 13, 2019).
256 See Aceves, supra note 253.
257 See id.

258 See id.
259 The e-cigarette industry has taken a page from tobacco manufacturers, developing
clever marketing strategies to attract youth to their products. See E-Cigarette Marketing
Continues to Mirror Cigarette Marketing, CAMPAIGN FOR TOBACCO FREE KIDS: BLOG

TOBACCO UNFILTERED (June 17, 2015), http://www.tobaccofreekids.org/blog/2015 06 17
_ecig [http://perma.cc/F73L-8Q7J]. A significant amount of e-cigarette marketing is done
via social media sites geared toward children and young adults, in which product
warnings and age restrictions are minimized. See Rick Nauert, Aggressive Online
Marketing of E-cigarettes May Target Teens, PSYCHCENTRAL (Aug. 8, 2018),
http://psychcentral.com/news/20 15/10/05/aggres sive-online-marketing-targets-teens-for-ecigarettes/93128.html [http://perma.cc/CZH9-9T2L].
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cigarette industry is reinventing itself,2 setting
the stage for new
0
chapters in smoking abatement battles.
As noted in the beginning of this Article, effective health
prevention and promotion is essential to the future of our health
system. Addressing population health challenges, like smoking
and accompanying nicotine addiction, have strong medical and
economic implications. Unless more effective approaches are
developed to reduce major preventable public health problems, no
systemic reform, whatever its character, will find the elusive
balance between cost and quality. To combat the ills of smoking
in its traditional and evolving forms, health authorities will need
to continue to apply established rules, as well as pursue new
approaches to regulation that have the capacity to reduce and
possibly eradicate this behavior. 26 1 As such, assessment of
abatement tools, such as product warnings, should be ongoing as
public health enforcement strategies must be adjusted to meet
current challenges, particularly in fluid areas like smoking.
In reviewing the history of tobacco regulations over the past
sixty years, mandatory product health warnings designed to
educate and deter consumption can be characterized as a
fundamental and lasting approach to smoking abatement. The
review of cigarette warning labels in this piece demonstrates
movement in regulation from modest textual warning
requirements in the 1960 laws, such as the Public Health
Cigarette Smoking Act, to the expansion of four rotational
warnings in the 1984 CSEA, and, more recently, to further
textual warnings and the addition of picture graphics in the 2009
TCA. While this movement is hardly rapid, it does reflect a
deeper understanding of the array of tobacco research and
expansion of knowledge about the physiological effects of
smoking, with a greater current focus on nicotine exposure from
OTPs, as well as a sustained commitment to the viability of
warnings as a key public health measure.

260 It is estimated that the e-cigarette market in 2018 in the United States was worth
$11.26 billion and is estimated, by 2024, to grow to $18.12 billion, with an increase in
online sales. See E-CigaretteMarket Growth, Trends and Forecast (2019 2024), MORDOR
INTELLIGENCE,
http://www.mordorintelligence.com/industry-reports/global-e-cigarettesmarket-industry [http://perma.cc/XE2Z-CQE7] (last visited Oct. 13, 2019); see also Josh
Constine, How Juul made vaping viral to become worth a dirty $38 billion, TECH CRUNCH
(Dec. 22, 2018, 10:58 AM), http://techcrunch.com/2018/12/22/juul-me-twice-shame-on-you/
[http://perma.cc/BQ5L-4RPA].
261 For a discussion on a British perspective on smoking eradication, a goal that
transcends borders, see Jason Murugesu, Will we ever stamp out smoking entirely?, NEW
STATESMAN AM. (Aug. 1, 2019), http://www.newstatesman.com/politics/health/2019/08/
will-we-ever-stamp-out-smoking-entirely [http://perma.cc/RDW7-HE8M].
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But nagging questions emerge from a review of tobacco
product label warnings. Are tobacco-warning labels necessary?
Are labels effective vehicles to inform and deter smoking? Can
changes be made in tobacco product labels to make them more
impactful? How should warnings be approached in the new
landscape of OTPs? Concerning the question of whether there is
a need to have warning labels, there are simply no voices of
opposition to these warnings. 2 2 They have garnered universal
domestic and international support as a core enforcement
mechanism from public health policy makers and regulators
alike.2 6 3 While product manufacturers and sellers may not
appreciate text warnings on packaging, there is no push back
from this sector on this requirement-on the menu of possible
controls, it does not impose a serious marketing impediment.26 4 In
fact, the e-cigarette manufacturers of their own accord, independent
of government directives, added a nicotine-warning label in
anticipation of the eventuality of such a mandate, and more
26 5
importantly, as a mechanism to deter product liability litigation.
The second question as to whether cigarette-warning labels
actually work opens a more controversial line of inquiry. Perhaps
President Nixon's guarded opinion about cigarette warnings,
noted earlier in this piece, was noteworthy as to the
government's responsibility to notify the public about known
dangers and let individuals choose to smoke or not. 266 President
Nixon characterized the science
driving warnings
as
controversial, but currently, with the exception of e-cigarettes,
the case against traditional tobacco is definitive, and the quest to
avoid dangers to health through safe cigarette alternatives still
26 7
remains a Sisyphean one.
President Nixon's other observation expressing doubt about
the effect of cigarette warnings on the public mirrors long
standing opinions on both sides of the smoking issue. As noted in
prior discussion, regulators, as early as 1967, frequently vented
their frustrations about the textual package warnings, and in

262 See Abby Ohlheiser, Big tobacco companies are putting big warning labels on their
e-cigarettes, WASH. POST (Sept. 29, 2014, 10:21 AM), http://www.washingtonpost.com/
news/to-your-health/wp/2014/09/29/big-tobacco-companies-are-putting-big-warning-labelson-their-e-cigarettes/ [http ://perma.cc/L55A-ZZHX].
263 See id.
264 See id.
265 See id.
266 See Whiteside, supra note 242.
267 See Laurie McGinley, Forget Those Occasional Cigarettes: There is No Safe
Smoking Level, WASH. POST (Dec. 5, 2016, 8:00 AM), http://www.washingtonpost.com/
news/to-your-health/wp/20 16/12/05/frget-those-occasional-cigarettes-there-is-no-safesmoking-level/ [http ://perma.cc/R23E -JUUV].
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fact, an outpouring of criticism about the ineffectiveness of such
regulation preceded every major tobacco bill. 26 8 The U.S., once
the leader in mandating tobacco warnings, fell behind in smoking
controls as other nations implemented graphic warning label
requirements, spurred by global tobacco abatement policies
adopted in the WHO's Framework Convention on Tobacco
Control.2 6 9 Eventually in 2009, with the passage of the TCA, the
U.S. joined the global community in finally requiring graphic
warning labels. 270 However, as discussed, the regulatory efforts
in the U.S. to implement graphic warnings have been stormy,
unsettled, and delayed.
Confronting the analytical question of whether text only or
graphic warnings work better to prevent and deter smoking
behavior places one into the murky waters of behavioral
economics. Some studies on the effectiveness of tobacco warnings
on youth and adult smokers conclude that textual warnings may
increase health knowledge and awareness of risk based on size
271
and design, but, at best, the results are tepid.
On the other hand, studies concerning the impacts of graphic
package warning labels are more positive. 272 One mega analysis
of the area concluded that graphic anti-smoking warnings could
elicit "maladaptive psychological responses"-in other words,
273
they could work.
No doubt package-warning labels offer a relatively
inexpensive mechanism to communicate with smokers at the
point of purchase; however, isolating the impacts of pictorial
warnings on behavior reduction, independent of other regulatory
controls, is largely a matter of speculation. Support for warnings

268 See Luca Paoletti et al., Current Status of Tobacco Policy and Control, 27 J.
THORACIC IMAGING 213, 215 (2012) ("A 1967 FTC report concluded that 'the warning label
on cigarette packages has not succeeded in overcoming the prevalent attitude toward
cigarette smoking created and maintained by the cigarette companies through their
advertisements, particularly the barrage of commercials on television, which portray
smoking as a harmless and enjoyable activity that is not habit forming and involves no
hazards to health."').
269 WORLD HEALTH ORG., supra note 166, at 9-10.
270 See Family Smoking Prevention and Tobacco Control Act, Pub. L. 11, 123 Stat.
1776 (codified as amended in 21 U.S.C. §§ 387, 387a-387u, 387a-1, 387f-1 (2012)).
271 See David M. Erceg-Hurn & Lyndall G. Steed, Does Exposure to Cigarette Health
Warnings Elicit Psychological Reactance in Smokers?, 41 J. APPLIED SOC. PSYCHOL. 219,
230 (2011); see also William G. Shadel et al., Do Graphic Health Warning Labels on
Cigarette Packages Deter Purchases at Point-of-Sale?An Experiment with Adult Smokers,
34 HEALTH EDUC. RES. 321, 321-31 (2019). The Shadel article notes that various types of

analyses on textual and pictorial tobacco warnings have found that pictorial warnings are
recalled more readily, generate more negative cognitions about smoking, and have greater
impacts on prevention and smoking reduction. Id.
272 See Erceg-Hurn & Steed, supra note 271, at 219.
273 See id.
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rests as much on intuition as fact. Review of American regulatory
history demonstrates that there is a long-standing belief that
textual warnings have little effect overtime-the use of graphic
labels has been delayed for almost ten years, so, as yet, there is
no experience with graphics in the U.S. American cigarette
marketplace. Perhaps a better gauge about the impacts of
warnings can be drawn from the reactions to expanded warning
labels on the part of the smoking industry. As text warnings are
relatively benign, occupying a side panel of cigarette packs,
displayed in similar fonts and colors blending with the overall
container, they became predictable and easily ignored. Graphic
warnings, on the other hand, featuring jarring images that
essentially change the character of the product package, have not
been met with industry acquiescence, but rather sparked
vigorous legal challenges that have foiled this initiative for over a
decade, which could be indicative of the fact that they may
actually work.
It is possible to envision an even more stringent and detailed
tobacco warning label requirement than the August 2019 graphic
warnings proposed rule, akin to labeling mandates for
over-the-counter drugs.2 74 Another direction that could be taken
is to adopt the approach of Australia and a number of other
countries that requires cigarettes to be sold in plain packages,
2 75
containing only a warning, without signature brand designs.
While plain packaging could be in our future, at this point,
graphic warning labels need to be adopted and their effectiveness
assessed over a number of years. Such regulatory impact
assessments need to occur in a more regular and timely manner
than was the case with prior warning label analyses and should
be based on more grounded methodological determinations of
costs and benefits. The fact that label warnings have been used
for many years should not establish them as permanent
regulatory strategies that are not frequently revisited and
updated-or even abandoned if they have lost their efficacy.
It would be wrong to suggest that the FDA has been a totally
absent regulator in the vaping arena.2 76 Since issuing the

274 See The Over-the-Counter Medicine Label: Take a Look, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/drugs/resources-you-drugs/over-counter-medicine-label-takelook [http://perma.cc/T3L7-SYBA] (last reviewed Sept. 27, 2017).
275 See Thomas Parker, From Uruguay to Saudi Arabia: 14 countries that have
implemented plain tobacco packaging, NS
PACKAGING
(May 28,
2019),
http://www.nspackaging.com/analysis/plain-tobacco-packaging/ [http://perma.cc/8C8F-5HEH].
276 See Katie Thomas & Sheila Kaplan, E-Cigarettes Went Unchecked in 10 Years of
Federal Inaction, N.Y. TIMES (Oct. 14, 2019, 5:12 PM), http://www.nytimes.com/2019/
10/14/health/vaping-e-cigarettes-fda.html [http://perma.cc/YT32-E7H3].
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deeming rule in 2016,277 the Administration's Center for Tobacco
Products ("CTP") has moved on a number of fronts to address
labeling, manufacturing, and marketing of ENDs products. 278 In
particular, emphasis has been placed on preventing youth sales
and use; conducting retailer and manufacturer checks; developing
product premarket authorization policies; and sponsoring and
promoting research. 279 In addition, the FTC is also involved in
e-cigarettes, as it continues its traditional role in policing unfair
and deceptive practices in the tobacco products arena. 280 However,
the recent outbreaks of serious lung damage in vapers rightly calls
28 1
into question the adequacy of the current regulatory structure.
The question arises as to whether the centralized regulatory
structure of the 2009 TCA is optimal to meet the challenges
posed by vaping-a practice that was barely in existence when
the TCA was enacted. Vaping-related lung disease, also known as
EVALI, has cast a bright light on the potential hazards in
e-liquids, sparking an awareness of both the complexity and lack
of knowledge of the underlying health exposures. 282 While
uniformity in federal regulatory approaches to e-cigarettes is
ultimately desirable, given this lack of certainty about the safety
of these diverse products and nicotine delivery devices, it may be
desirable to consider involvement of other regulatory actors, and
processes in framing warning labels in the ENDs area. 28 3 It is
noteworthy that in the 2020 Trump-proposed federal budget
there is a recommendation that a new tobacco control agency be
created in the Department of Health28 4 and Human Services,
stripping the FDA of this responsibility.

277 The decision to regulate combustible cigarettes as tobacco products, primarily
under FDA auspices, is the result of many years of effort to centralize tobacco regulation
that culminated in the 2009 TCA.
278 See Ned Sharpless, How FDA is Regulating E-Cigarettes, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/how-fdaregulating-e-cigarettes [http://perma.cc/ZB8P-LZ7J] (last updated Sept. 10, 2019).
279 See id.
280 See Jennifer Maloney, Juul's Marketing Practices Under Investigation by FTC,
WALL STREET J. (Aug. 29, 2019), http://www.wsj.com/articles/juuls-marketing-practicesunder-investigation-by-ftc- 11567096073 [http://perma.cc/7F28-67EC].
281 See Michael Siegel, POV New FDA Regulations on Vaping Products a Failure,
BU TODAY (July 13, 2016), http://www.bu.edu/articles/2016/fda-vaping-regulations
[http://perma.cc/VBB8-N7FG].
282 See Jennifer E. Layden et al., Pulmonary Illness Related to E-Cigarette Use in
Illinois and Wisconsin Preliminary Report, NEW ENG. J. MED. (Sept. 6, 2019),
http://www.nejm.org/doi/full/10.1056/NEJMoa 1911614 [http://perma.cc/K89Y-ND2L].
283 See What is Vaping?, VAPING, http://vaping.org/ [http://perma.cc/DDP-8XSX] (last
visited Oct. 13, 2019).
284 Nicholas Florko, Trump Doesn't Want the FDA to Regulate Tobacco, STAT (Feb.
10, 2020), http://www.statnews.com/2020/02/10/trump-doesnt-want-the-fda-to-regulatetobacco/ [http://perma.cc/C68W-U62H]. It is difficult to pinpoint the motivations for this
proposal with certainty. On the one hand, the FDA can be seen as a tepid regulator, slow
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The FDA regulatory scheme for e-cigarette products follows the
dictates of the 2009 TCA and is actualized through the
Administration's deeming rule. Other regulatory avenues within
the Food, Drug, and Cosmetic Act ("FDCA") have not been pursued
since the Supreme Court decision in FDA v. Brown & Williamson
that held that tobacco products, as marketed, could not be
regulated under the FDCA, triggering the subsequent enactment
of the TCA 2 85 While the Brown & Williamson case appears to be
superseded by the TCA, the 2009 regulatory scheme does not allow
tobacco products, without therapeutic value, to be explicitly
regulated as either a drug or medical device. 2 86 A federal court in
Sottera v. FDA reiterated Brown & Williamson in upholding an
e-cigarette manufacturer's argument that their products could not
be regulated separate from the TCA 2 87 At issue in Sottera was
whether e-cigarettes could be regulated as unapproved drug device
combinations.2 88 It is noteworthy that a key factor in the Sottera
analysis limiting the FDA's authority is that the product at issue
was not being sold for therapeutic purposes, but rather
recreational.2 89 The conclusion can be made that a device sold for
therapeutic purposes would fall within the ambit of
Administration oversight as a drug/medical device.290 It is evident
that e-cigarettes are being promoted to adults for smoking
cessation, and as such, may be regulated as a type of medical
device.2 91 This opens the door to another possibility, beyond the
TCA scheme, for additional e-cigarette FDA action-such as

to act against the threats posed by the explosion in e-cigarettes, and generally
overwhelmed by its overall mandates. But on the other hand, the FDA tobacco regulatory
structure is well developed and embodies the requisite authority to be a meaningful public
health authority in the e-cigarette arena. Creating a new regulatory body may only serve
to further delay necessary oversight at a time when both the products and their markets
are far ahead of government control.
285 FDAv. Brown & Williamson Tobacco Corp., 529 U.S. 120, 143 (2000).
286 See Clarification of When Products Made or Derived From Tobacco Are Regulated
as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding
"Intended Uses," 82 Fed. Reg. 2,193 (Jan. 9, 2017) (to be codified at 21 C.F.R. pts 201, 801,
and 1100).
287 Solterra, Inc. v. FDA, 627 F.3d 891, 897-98 (D.C. Cir. 2010).
288 See id. at 892.

289 See id. at 898. Therapeutic purposes under the FDCA include use in the diagnosis,
cure, mitigation, treatment, or prevention of disease, according to 21 U.S.C. § 321 (g)(1)
(2018). See id. at 893-94.
290 See Clarification of When Products Made or Derived From Tobacco Are Regulated
as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding
"Intended Uses," 82 Fed. Reg. 2,193.
291 See Esther Wang, Juuling Is Fine, Actually (For Adults Who Want to Quit
Smoking Cigarettes), JEZEBEL (Sept. 30, 2019, 2:05 PM), http://jezebel.com/juuling-isfine-actually-for-adults-who-want-to-quit-1838622453 [http://perma.cc/Z9EU-FDZM]; see
also Belinda Borrelli & George T. O'Connor, E-Cigarettes to Assist with Smoking
Cessation, 380 NEw ENG. J. MED. 678, 678 (Feb. 14, 2019), http://www.nejm.org/doi/
full/10.1056/NEJMe1816406 [http://perma.cc/8N52-4TUN].
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regulating ENDs as over-the-counter medical devices. As an OTC
device, it is comparable to other tobacco prevention products.
ENDs devices and e-liquids would need to meet more detailed
labeling requirements under FDA-OTC regulations. 292 Under
device labeling mandates, the FDA can tailor an OTC product
label to include additional information that is specific to a given
health concern and make revisions as new research unfolds.
Presently, the FDA can move closer to declaring an OTP as
"safer" if the product undergoes a more rigorous review and
demonstrates a lower risk to smokers ("MRTP," or modified risk
tobacco product). 293 It is unclear, however, if an MRTP approval
can allow the OTP manufacturer to claim that the ENDs device
is actually a smoking cessation device. 294 Such a claim goes
beyond a stipulation that295the smoking product is "safer" into the
realm of medical devices.
Vaping entails igniting a chemical cocktail of ingredients,
some of which may be quite harmful.296 As such, regulatory
oversight could benefit from expanding e-cigarettes into the
purview of the Federal Hazardous Substances Act ("FHSA"),
under the jurisdiction of the U.S. Consumer Products Safety
Commission ("CPSC"). 297 The current FDA deeming rule could be
strengthened by inclusion of an additional warning mandate
focused on chemical exposure; a joint agency-labeling scheme with
input from the CPSC concerning hazardous chemicals content
would be a more robust labeling scheme. It appears that vaping
chemicals meet the criteria required for application of labeling
mandates under the FHSA. 298 At the time cigarettes were
excluded from FHSA jurisdiction by Congress, smoking products
did not extend beyond use of plant-based medium, but now clearly
fall into the realm of hazardous chemicals. 299 Broadening CPSC

292 See General Device Labeling Requirements, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/medical-devices/device-labeling/genera1-device-labeling-requirements
[http://perma.cc/36ZE-WLUY] (last updated Mar. 27, 2018) (citing 21 C.F.R. § 801 (2018)).
293 See Modified Risk Tobacco Products, supra note 160.
294 See id.
295 See id.

296 See Carley Thompson, Meet the 5 Chemicals You Didn't Know Were in Vaping
Products, PUB. HEALTH INSIDER (June 14, 2017), http://publichealthinsider.com/2017/06/
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jurisdiction to include e-cigarette regulation builds3 on existing
Commission authority to regulate e-liquid containers. 00
Warning label jurisdiction should be expanded to the state
level in keeping with the TCA, which generally carves out a
greater role for state and local government involvement in
tobacco regulation. During this period of uncertainty, it seems
reasonable for states to have authority to add their own warning
language to e-cigarette products, provided a given state can make
the case that the additional information being added to a
warning fosters public health interests. Unlike traditional
cigarettes, where regulation is the byproduct of years of study,
the uncertainties surrounding ENDs products could benefit from
regulatory initiatives warranting experiments with use of a
variety of OTP warning labels.
Warning labels are only one strategy that can be identified
in the long history of cigarette abatement, and as noted in this
piece, they are not foolproof and need to be continually assessed
and amended to reflect changes in science and public response.
However, in the face of e-cigarette triggered lung disease,
warning labels take on a significant role in filling a regulatory
void in the midst of a public health emergency. Unless these
products are actually banned, it becomes critical to both
strengthen e-cigarette warnings and expand the field of
regulators and their responsibilities for crafting these new
vaping warnings. E-cigarette and e-liquid warning labels should
go beyond a brief statement about nicotine and also warn about
the danger of inhaling chemical constituents of e-liquids that are
carriers for the nicotine. The warnings should state that vaping
products are dangerous and that it is recommended by medical
authorities that individuals refrain from the recreational use of
the product, as this practice may result in serious lung damage.
Once e-cigarettes and e-liquids have undergone successful
premarket review by the FDA, that should also be noted on the
product label. In addition, like a food label, the chemical content
in the e-cigarette ought to be disclosed, listed on the package, and
jointly regulated by the CPSC.
The arguments made by this new industry that e-cigarettes
can lead to smoking cessation should not be casually dismissed
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[http://perma.cc/R5N2-BPTE]; see
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but need to be verified through extensive scientific research. The
newest entry into the OTP market, the Philip Morris I Quit
Ordinary Smoking ("IQOS"), is a heat-not-burn cigarette device
that has obtained an FDA Premarket Tobacco Application
("PMTA"). 30 1 The IQOS approval was granted based on the
conclusion that this heat-not-burn product produces fewer or
lower levels of toxins than traditional cigarettes. 3 2 The FDA
stresses that the award of the PMTA does not mean that the
product is safe, and that the IQOS will be considered a cigarette,
necessitating that they meet current labeling and advertising
restrictions. 3 3 The FDA decision is not without controversy, as
health advocates have pointed out the lack of research, beyond
Philip Morris' own study, that the IQOS actually helps
individuals either reduce smoking generally or that the product
30 4
is any safer for an individual's lungs and immune system.
VII. CONCLUSION
In the annals of public health, few issues have garnered as
much attention as cigarette smoking. Although dramatic
progress has been made in smoking abatement, the emergence
and rapid proliferation of other tobacco products, especially
e-cigarettes, results in new challenges emerging in this arena.
Package label warnings continue to be a foundational regulation
needed to both educate and deter, dating back to the 1970s-the
period in which the 91st Congress enacted the Public Health
Cigarette Smoking Act. As smoking sparked multiple regulatory
interventions, it is difficult to isolate the singular contribution of
package warnings in isolation from other abatement measures.
The review of the legislative history of tobacco label regulations
leads to the conclusion that text-only warnings appear to have
had diminishing returns on smoking prevention and cessation.
While graphic warnings have garnered global support, there is
simply no American experience with this approach and judging
their impact prior to implementation, even in the face of more
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Control Act's PMTA & MRTP Provisions Mean to Protect the USA From Any New Tobacco
Products That Will Not Reduce Health Harms But FDA Isn't Cooperating, J. HEALTH
CARE L. & POL'Y, (forthcoming 2020).

302 See id.
303 See id.
304 See Lisa Rapaport, 'Heat-not-burn'cigarettes still damage lungs, REUTERS (Sept. 18,
2018, 10:15 AM), http://www.reuters.com/article/us-health-iqos/heat-not-burn-cigarettesstill-damage-lungs-idUSKCN1M12CB [http://perma.c/48NZ-S33W].

2020]

Tobacco Product Warnings in the Mist of Vaping

extensive research, is still a matter of speculation. On the other
hand, it seems clear that current e-cigarette warnings need to be
strengthened, and until the FDA engages in complete review of
e-cigarette products, including e-liquids, multiple regulators
should be encouraged to contribute to the development of more
impactful product warnings.
President Nixon's reflection on cigarette warnings, a half
century ago, which concluded that the government's role is to
simply provide information about risks and let individuals
choose, belies the need for vigilance in addressing this ongoing
public health challenge. Our society has paid, and continues to
pay, a very high price in placating economic and alleged liberty
interests related to tobacco.30 5 Both individual and population
health demand maintenance of an aggressive posture in the
smoking area, as this behavior has significant implications on
the financial sustainability of the broader health system and the
future of reforms in this sector.

305 See Gallagher v. City of Clayton, 699 F.3d 1013, 1017-18 (8th Cir. 2002).

